[{"text": "PREMIUM Jefferies Upgrades Crinetics Pharmaceuticals to Buy From Hold, $55 Price Target MT Newswires Wed, Jan 22, 2025, 3:13 PM In This Article: CRNX -3.75% Crinetics Pharmaceuticals (CRNX) has an average rating of Buy and mean price target of $75.43, accor PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2025-01-22T15:13:41", "sentiment": {"score": 0.044563173316419125, "confidence": 0.0570184625685215, "probabilities": {"positive": 0.0570184625685215, "negative": 0.012455289252102375, "neutral": 0.9305261969566345}}, "embedding": [-0.13890758156776428, -0.29805707931518555, -0.03617383539676666, -0.09061796218156815, 0.11133702844381332, -0.013170923106372356, 0.09751280397176743, 0.22221821546554565, 0.06744619458913803, 0.08809417486190796, -0.10457369685173035, 0.05175426974892616, 0.12564679980278015, -0.03692985698580742, -0.1074926033616066, -0.036327555775642395, 0.06825415790081024, -0.185953289270401, 0.17686773836612701, 0.02578241564333439, -0.20731499791145325, 0.12004608660936356, 0.03070817142724991, 0.0644785687327385, 0.047372687608003616, -0.0023519776295870543, -0.05639513209462166, 0.05301262438297272, 0.06656992435455322, 0.1217980906367302, -0.1055828332901001, 0.028402237221598625, 0.05668708682060242, -0.05729885771870613, 0.02363879792392254, 0.037452779710292816, -0.07505132257938385, 0.009452961385250092, -0.14056050777435303, 0.1271909475326538, -0.027680419385433197, 0.07134654372930527, -0.13258704543113708, -0.03253663703799248, 0.02246895618736744, -0.2399933934211731, -0.0066221654415130615, 0.1852523386478424, 0.2069271206855774, 0.22712206840515137, -0.08411853760480881, -0.24137628078460693, 0.046424511820077896, -0.024004466831684113, -0.022447440773248672, 0.17014138400554657, -0.43724963068962097, -0.0453527495265007, 0.08446840196847916, -0.023723071441054344, -0.04007071256637573, -0.047637492418289185, -0.09957599639892578, -0.005090374033898115, 0.10169181227684021, 0.04077773168683052, 0.017335597425699234, 0.01895163394510746, 0.11879098415374756, 0.017141513526439667, 0.06021720916032791, 0.048515111207962036, 0.073664590716362, -0.19478991627693176, 0.01250428706407547, 0.15321940183639526, 0.24538598954677582, -0.19691981375217438, -0.033812183886766434, -0.09011069685220718, -0.09851255267858505, -0.2304157167673111, 0.0462232269346714, -0.14407995343208313, 0.07991847395896912, 0.005000825505703688, 0.3189886510372162, 0.13775043189525604, 0.12743505835533142, 0.0585184209048748, 0.17807628214359283, 0.010302734561264515, 0.09870082139968872, -0.17134462296962738, -0.15201762318611145, 0.09189912676811218, -0.14325866103172302, 0.07760793715715408, -0.03091295436024666, 0.030316296964883804, 0.1358313411474228, 0.1441696435213089, -0.07232493162155151, -0.11201218515634537, -0.09696922451257706, -0.05587046593427658, 0.06954653561115265, 0.25274646282196045, 0.00033531402004882693, 0.025112126022577286, -0.12208054959774017, 0.11568104475736618, 0.01550871878862381, -0.1351485401391983, -0.05652673542499542, 0.19369958341121674, -0.22324486076831818, -0.16666175425052643, 0.21529962122440338, -0.05018632858991623, -0.08467807620763779, 0.026821419596672058, -0.18411089479923248, -0.11356212198734283, -0.012041887268424034, 0.010981440544128418, -0.07445833086967468, 1.3141010039579713e-32, -0.19040639698505402, 0.18761296570301056, 0.0640455037355423, -0.20123645663261414, -0.11930776387453079, 0.11622798442840576, 0.022222744300961494, 0.09507529437541962, -0.25327005982398987, -0.14961868524551392, -0.25108131766319275, 0.22330136597156525, -0.15439274907112122, 0.06907851994037628, -0.1650456339120865, -0.29804861545562744, 0.0732952356338501, 0.11149546504020691, 0.1506146937608719, 0.05042898282408714, -0.12938867509365082, 0.024221306666731834, -0.050786394625902176, 0.0921785905957222, -0.08566626906394958, 0.003108600154519081, 0.15227045118808746, 0.24524475634098053, 0.1959943026304245, 0.021961992606520653, -0.12755811214447021, 0.07629410922527313, 0.14060042798519135, -0.04495228826999664, -0.05315908044576645, -0.05479889735579491, -0.04626687243580818, -0.1213870421051979, -0.0014400242362171412, -0.10177594423294067, -0.06352977454662323, 0.18112018704414368, -0.1780589520931244, -0.08278838545084, -0.07994762808084488, -0.13997018337249756, -0.043744176626205444, -0.0779709741473198, -0.04178101196885109, -0.12374833971261978, -0.157669797539711, 0.15421074628829956, -0.05709234997630119, -0.02979595772922039, -0.25098979473114014, -0.08271677792072296, -0.08005370944738388, -0.1077016219496727, 0.13763117790222168, 0.09196054935455322, 0.08240367472171783, 0.08315476775169373, 0.1245127022266388, -0.08704483509063721, -0.09197180718183517, 0.23935163021087646, -0.12289737910032272, -0.2210434228181839, -0.06153564155101776, 0.16400954127311707, 0.0850592777132988, -0.037744712084531784, 0.04488462209701538, 0.026798978447914124, 0.31295761466026306, -0.06009732186794281, -0.12344266474246979, -0.027186017483472824, 0.09965807944536209, 0.17009013891220093, 0.00555969076231122, -0.14348113536834717, 0.07221575826406479, 0.10519840568304062, 0.1129172295331955, -0.07918251305818558, -0.11496073007583618, 0.04798749461770058, 0.10191886872053146, 0.06570416688919067, 0.061308879405260086, -0.15466205775737762, -0.15835167467594147, 0.16860002279281616, -0.07523353397846222, -1.0581775901531246e-32, -0.04454510658979416, -0.030420644208788872, 0.0422172024846077, 0.14719395339488983, -0.17183010280132294, 0.14990319311618805, -0.12427369505167007, 0.0867084413766861, 0.19049915671348572, -0.040600769221782684, 0.170781672000885, 0.11214961856603622, -0.13021054863929749, -0.011643518693745136, 0.01854276843369007, 0.0036086661275476217, 0.02641078643500805, -0.1163172796368599, 0.038673896342515945, -0.08728116005659103, 0.061673641204833984, 0.14107993245124817, -0.006668210960924625, 0.3222326934337616, -0.04078482463955879, 0.08039280027151108, 0.04347863420844078, 0.150624617934227, 0.10576602071523666, 0.09101516753435135, -0.13984160125255585, -0.15773290395736694, -0.15449859201908112, 0.16755464673042297, -0.08604053407907486, 0.055468637496232986, 0.249874085187912, 0.07884795218706131, 0.07529386878013611, 0.03785517439246178, 0.1845012754201889, -0.02580854296684265, -0.014829061925411224, 0.010682283900678158, 0.14067116379737854, -0.0328802764415741, -0.005148628726601601, 0.07960569858551025, 0.06949737668037415, -0.03710055351257324, -0.18363477289676666, -0.009799428284168243, 0.1111159399151802, -0.03601602837443352, -0.029897456988692284, 0.13934241235256195, -0.037047021090984344, 0.20108798146247864, 0.12635844945907593, 0.05939118191599846, 0.12215609103441238, 0.06961950659751892, -0.30468857288360596, -0.10611250251531601, 0.09061015397310257, 0.13992874324321747, -0.008163007907569408, 0.043587155640125275, 0.0792347714304924, -0.1116458848118782, -0.017162829637527466, -0.043914467096328735, 0.22763657569885254, -0.12065672129392624, -0.05204247683286667, 0.08512532711029053, 0.001700839027762413, -0.19669507443904877, -0.07908795773983002, -0.024121161550283432, 0.09705448150634766, -0.12936170399188995, 0.10392390191555023, 0.04900069162249565, -0.1336234211921692, 0.0483827218413353, 0.06851132214069366, -0.09317462146282196, -0.11157485097646713, 0.0838356763124466, -0.06516639143228531, -0.11750832945108414, -0.0780004933476448, -0.04104983061552048, 0.06033460795879364, -9.902500153202709e-08, 0.08399936556816101, -0.008265143260359764, 0.21103954315185547, 0.11505059152841568, 0.05329384654760361, 0.13232369720935822, 0.03272392973303795, 0.015907196328043938, 0.019497090950608253, 0.23599137365818024, -0.09125392884016037, -0.14114274084568024, -0.01577308028936386, 0.0031758593395352364, -0.2724491357803345, 0.08114299923181534, -0.07305531948804855, 0.08673718571662903, 0.004754229914397001, -0.14362674951553345, -0.054494623094797134, 0.09482262283563614, 0.20489273965358734, 0.03642193228006363, 0.071597158908844, -0.009237898513674736, -0.030595984309911728, 0.1830582320690155, -0.03379979729652405, 0.03042108379304409, -0.10853777825832367, -0.0665583461523056, 0.13588988780975342, 0.0912761464715004, 0.04856400936841965, -0.12537606060504913, -0.13977722823619843, 0.15965409576892853, -0.030680038034915924, 0.008854653686285019, 0.0024305591359734535, -0.12291430681943893, -0.13962702453136444, -0.017210667952895164, -0.0690261498093605, -0.018876424059271812, -0.22918075323104858, -0.05429736524820328, 0.15100228786468506, -0.13840915262699127, 0.338743656873703, -0.010187284089624882, 0.07537383586168289, 0.011456107720732689, 0.042668186128139496, -0.10443531721830368, -0.10263554006814957, -0.21568599343299866, -0.07993507385253906, 0.020801784470677376, -0.04020921513438225, -0.28578558564186096, -0.047840967774391174, 0.0330229327082634], "changes": {"1wk": -1.1125492579550498}}, {"text": "Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman\u2019s Long-Term Stock Picks? Usman Kabir Wed, Jan 22, 2025, 12:10 AM 4 min read In This Article: CRNX -3.75% We recently published a list of Billionaire Joseph Edelman's Top 10 Long-Term Stock Picks . In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands against other Billionaire Joseph Edelman\u2019s long-term stock picks. Joseph Edelman is a renowned figure in the investment world, recognized for his expertise in biotechnology and healthcare investing. As the founder, CEO, and portfolio manager of Perceptive Advisors , Edelman has built a reputation as one of the most successful and insightful investors in the biotech sector. His deep understanding of the scientific, clinical, and financial aspects of the industry has enabled him to identify promising companies and generate significant returns for his investors. Joseph Edelman earned his Bachelor of Arts in Psychology from the University of California, San Diego, and later pursued an MBA from NYU Stern School of Business. He began his career as a biotechnology analyst at Prudential Securities and subsequently worked as a portfolio manager at Paramount Capital Asset Management. These early roles provided Edelman with a foundation in analyzing biotech companies, understanding their value drivers, and assessing the risks associated with drug development and regulatory approval processes. Read more about these developments by accessing 10 Best AI Data Center Stocks and 10 Buzzing AI Stocks According to Goldman Sachs . In 1999, Edelman founded Perceptive Advisors, a New York-based investment firm focused on the life sciences sector. The firm initially launched with a single hedge fund, the Perceptive Life Sciences Fund, and has since expanded to manage billions of dollars in assets. Perceptive Advisors specializes in identifying high-growth potential in emerging biotech, pharmaceutical, and healthcare companies, with an emphasis on innovation in areas such as gene therapy, oncology, and rare diseases. Under Edelman\u2019s leadership, Perceptive Advisors has achieved remarkable success. The firm manages over $4.7 billion in the 13F portfolio as of the end of the third quarter of 2024. The Perceptive Life Sciences Fund has delivered annualized returns exceeding 15% over the past two decades, far outpacing broader market indices. Edelman has been an early backer of biotech companies that went on to achieve significant breakthroughs, including Moderna and CRISPR Therapeutics. While Edelman\u2019s track record is stellar, the biotech sector\u2019s inherent risks mean that not all investments succeed. Regulatory setbacks, clinical trial failures, and market sentiment can lead to significant volatility. Story Continues Read more about these developments by accessing 30 Most Important AI Stocks According to BlackRock and Beyond the Tech Giants: 35 Non-Tech AI Opportunities . For this article, we selected stocks by combing through the 13F portfolio of Perceptive Advisors at the end of the third quarter of 2024. Only the companies that have been in the 13F portfolio of the fund consistently for the past three years were selected. These stocks are also popular among other hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). Is Crinetics Pharmaceuticals, Inc. (CRNX) Among Billionaire Joseph Edelman\u2019s Long-Term Stock Picks? A doctor and a patient discussing the success of the clinical trial for a new nonpeptide somatostatin receptor agonist. Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Number of Hedge Fund Holders: 37 Perceptive Advisors\u2019 Stake: $5.1 million Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a pharmaceutical company that develops much-needed therapies for people with rare endocrine diseases. The following factors make the firm an appealing investment choice. Firstly, significant financial growth was seen as per the reports of the third quarter of 2024, illustrating $862.7 million in cash, cash equivalents, and investment securities as compared to $558.6 million in the previous year. Secondly, another project that makes this company worth investing in is the launch of an oral treatment for Acromegaly. Crinetics Pharmaceuticals (NASDAQ:CRNX) has announced the approval of its New Drug Application (NDA) for the treatment and long-term maintenance therapy of acromegaly in adults. Overall, CRNX ranks 10th on our list of Billionaire Joseph Edelman\u2019s long-term stock picks. While we acknowledge the potential of CRNX as an investment, our conviction lies in the belief that some stocks hold greater promise for delivering higher returns, and doing so within a shorter time frame. If you are looking for a stock that is more promising than CRNX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2025-01-22T00:10:16", "sentiment": {"score": 0.33443354442715645, "confidence": 0.34412476420402527, "probabilities": {"positive": 0.34412476420402527, "negative": 0.00969121977686882, "neutral": 0.646183967590332}}, "embedding": [-0.037370409816503525, -0.1045483946800232, -0.07452642172574997, -0.0825430154800415, -0.04675530269742012, -0.03862188011407852, -0.003610210493206978, 0.11373785138130188, 0.11427991837263107, -0.0014714989811182022, -0.08031348884105682, 0.1379961520433426, 0.0051660905592143536, 0.015202155336737633, -0.1759101152420044, 0.06383898854255676, -0.0203543771058321, 0.0037433700636029243, -0.09016342461109161, 0.07927695661783218, -0.11249712854623795, -0.08259284496307373, 0.026273341849446297, -0.02533167228102684, -0.0365719236433506, 0.006422082893550396, -0.026642415672540665, 0.0019863732159137726, -0.2104613035917282, 0.012655454687774181, 0.11077539622783661, 0.08966928720474243, 0.05686209350824356, -0.04181508719921112, -0.01231034193187952, 0.1856592893600464, -0.04880676046013832, 0.14327672123908997, -0.013424161821603775, 0.014587737619876862, 0.02429685927927494, -0.049828432500362396, -0.06735999882221222, 0.07358413189649582, 0.11474190652370453, -0.21289736032485962, -0.006376320496201515, -0.01719549484550953, 0.058323800563812256, 0.04303593933582306, -0.3240138292312622, -0.17394721508026123, 0.11271677911281586, -0.08217205107212067, -0.1006600558757782, 0.0943334773182869, -0.11176501959562302, 0.10973919928073883, -0.040674395859241486, 0.03092661313712597, 0.045896805822849274, -0.11106330901384354, 0.06766512989997864, -0.0047668516635894775, 0.10311581194400787, 0.06298784911632538, 0.018985677510499954, 0.02453121729195118, -0.01862199231982231, -0.0544135682284832, 0.13294139504432678, -0.08279342949390411, -0.03519104793667793, 0.011936246417462826, 0.05907867103815079, 0.03992675244808197, 0.02694522775709629, 0.08277459442615509, 0.11512787640094757, -0.15417060256004333, 0.12865115702152252, 0.007405025884509087, -0.03769328445196152, -0.016391677781939507, -0.05544145405292511, 0.006064561195671558, -0.004099116660654545, 0.02687169425189495, 0.10237792134284973, 0.09616542607545853, 0.015105978585779667, -0.09249474853277206, -0.006422797217965126, -0.0664336308836937, 0.02973397821187973, 0.026576712727546692, -0.11302463710308075, -0.02067592926323414, -0.1064123809337616, -0.02807043492794037, 0.0010745441541075706, 0.08218736201524734, -0.10461719334125519, 0.06426436454057693, -0.03861687704920769, -0.07917794585227966, 0.06976673007011414, 0.053691521286964417, 0.07072638720273972, 0.05370575934648514, -0.1303064525127411, 0.18269367516040802, -0.07766357064247131, 0.04409385472536087, 0.07597281783819199, 0.018177971243858337, -0.04945099353790283, 0.07111433148384094, 0.2294100522994995, -0.010084711015224457, 0.003428754163905978, 0.05844683200120926, -0.12386282533407211, -0.09147016704082489, -0.0316627211868763, -0.06028924137353897, -0.17589852213859558, 1.3034253112005971e-32, -0.08578869700431824, 0.20739082992076874, 0.11581412702798843, 0.11736442893743515, -0.13571056723594666, 0.017554964870214462, -0.010224070399999619, -0.005916228052228689, -0.15549537539482117, -0.12022082507610321, -0.02921760268509388, 0.15878546237945557, -0.015953902155160904, 0.08717983961105347, -0.09865221381187439, -0.1310652792453766, -0.03895600140094757, 0.0264473557472229, 0.05361015349626541, -0.09535343945026398, -0.0830700621008873, 0.038468167185783386, -0.11260789632797241, -0.037716057151556015, -0.06261754781007767, -0.07267089188098907, 0.038308415561914444, 0.1222170889377594, 0.02529197372496128, 0.03973030298948288, -0.03144865483045578, 0.10363680124282837, -0.07453314960002899, -0.11380307376384735, 0.010319335386157036, -0.08098158240318298, -0.08471660315990448, -0.12924179434776306, 0.09629423916339874, 0.07943368703126907, -0.11958271265029907, 0.13180971145629883, 0.01564977318048477, -0.05406239256262779, -0.08433196693658829, 0.03808979317545891, 0.08458022028207779, 0.1551293134689331, 0.0753576010465622, -0.10238562524318695, -0.033067189157009125, 0.01634529046714306, 0.04897547513246536, -0.13516241312026978, -0.014357351697981358, 0.03805190697312355, -0.09020119905471802, -0.05552366375923157, 0.010005670599639416, 0.059601183980703354, 0.016148049384355545, 0.11851119250059128, -0.08439141511917114, 0.1260964572429657, -0.059109143912792206, 0.11746881902217865, -0.028058871626853943, -0.025405671447515488, 0.03971682861447334, 0.1978929340839386, -0.012650929391384125, 0.0010845862561836839, 0.12561474740505219, -0.06609954684972763, -0.0173790380358696, -0.08110873401165009, -0.05595412850379944, 0.09419594705104828, -0.008555089123547077, 0.1459527313709259, 0.10427805781364441, 0.011828889138996601, 0.009871868416666985, 0.012915028259158134, -0.04459403082728386, 0.010440117679536343, 0.019986137747764587, 0.016341708600521088, 0.07217337936162949, 0.05023670196533203, 0.07810992747545242, -0.13727334141731262, 0.026889989152550697, 0.09367353469133377, -0.08527800440788269, -1.056882709657297e-32, -0.11475460231304169, -0.14027628302574158, 0.04096204787492752, -0.02621016651391983, 0.028708389028906822, -0.019442157819867134, -0.005207959562540054, -0.050455279648303986, 0.0632002204656601, -0.10326492786407471, 0.06974619626998901, 0.056870002299547195, 0.009850086644291878, -0.07332146912813187, -0.08620905876159668, 0.06334657967090607, -0.04126841574907303, -0.11627237498760223, -0.058191582560539246, -0.1235828772187233, 0.0894896537065506, 0.1204104945063591, -0.10565204918384552, 0.13257452845573425, -0.05140307545661926, 0.12234745919704437, 0.04918975755572319, 0.1786399930715561, -0.007629655301570892, -0.028321420773863792, -0.065623939037323, -0.016452820971608162, -0.21665623784065247, 0.03447085618972778, -0.03823937475681305, 0.05346709489822388, -0.10057112574577332, -0.15281474590301514, 0.0007241326384246349, -0.05129878968000412, 0.11309541761875153, -0.02326214872300625, -0.032158009707927704, -0.07905426621437073, 0.05885763093829155, 0.0480564646422863, 0.02569918893277645, 0.10194085538387299, 0.10178425908088684, 0.03014533594250679, -0.07228545844554901, 0.1337248682975769, -0.0069098155945539474, -0.041011251509189606, 0.011984341777861118, -0.05163666605949402, 0.05047839879989624, 0.029235541820526123, 0.08030149340629578, -0.03426047042012215, 0.03239379823207855, 0.06059567257761955, 0.028627613559365273, 0.1101306676864624, -0.1259370595216751, -0.0015648354310542345, 0.057797715067863464, 0.03914632648229599, -0.04700838774442673, -0.08125030994415283, 0.03458298370242119, -0.05496304854750633, 0.10125131905078888, -0.16999714076519012, -0.06282782554626465, 0.15326231718063354, -0.11590465158224106, -0.1628505289554596, -0.15795627236366272, 0.05815404653549194, 0.022742386907339096, -0.1304108202457428, -0.007453429512679577, 0.12318776547908783, 0.012638620100915432, 0.11090844869613647, -0.016759444028139114, -0.09389334917068481, -0.024699509143829346, -0.04363730549812317, 0.0404122918844223, -0.164035826921463, -0.09926910698413849, 0.05028894171118736, 0.06441918015480042, -1.0046817777720207e-07, 0.10197566449642181, -0.08405861258506775, 0.08697168529033661, -0.11988221108913422, 0.032160066068172455, -0.04221503436565399, -0.018182789906859398, 0.04080134257674217, 0.08000116795301437, 0.17293226718902588, -0.04019613564014435, 0.04597632959485054, -0.11065735667943954, 0.08274897933006287, -0.06133880093693733, -0.0038216067478060722, 0.023581769317388535, -0.02499011531472206, -0.012243052944540977, 0.020640747621655464, 0.04938272386789322, 0.04723713546991348, 0.029010465368628502, -0.006018708925694227, 0.09309414774179459, -0.01742703653872013, 0.01324152760207653, -0.02702503278851509, -0.01880316063761711, 0.08352389186620712, 0.026440536603331566, -0.1281355321407318, 0.11481359601020813, 0.004129667300730944, 0.021916527301073074, -0.02942301705479622, 0.1039547324180603, 0.04906415566802025, -0.006211321800947189, 0.10213778913021088, -0.0062966784462332726, -0.01914283260703087, 0.026227526366710663, 0.08804941177368164, -0.07870976626873016, -0.06207697466015816, -0.0822671502828598, 0.08160074055194855, 0.0941738411784172, -0.08164414763450623, 0.0988612174987793, -0.012445828877389431, 0.0011845240369439125, -0.060663774609565735, -0.0016651423647999763, 0.02613450028002262, -0.014593069441616535, -0.09543189406394958, -0.10364444553852081, 0.008895373903214931, 0.07986587285995483, -0.11892303079366684, 0.08407856523990631, 0.0377778559923172], "changes": {"1wk": -1.3931814350210678}}, {"text": "Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential Noor Ul Ain Rehman Fri, Jan 17, 2025, 8:12 AM 5 min read In This Article: CRNX +1.59% We recently published a list of the 12 Biotech Stocks with the Biggest Upside Potential . In this article, we are going to take a look at where Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech Stocks While 2024 was a \u201cchallenging\u201d year for biotech stocks, JPMorgan is of the view that some names in the industry may be poised for considerable upside in the coming months. On November 28, Johan Hueffer, senior partner and principal of investments at Novo Holdings, appeared on CNBC to discuss his macro perspective on investments in life sciences. He said that biotechs faced difficulty raising capital in the last couple of years. However, that trend has started to improve in the last quarter or two. Still, there have been impacts on companies that particularly service the pharmaceutical industry, such as contract research organizations (CROs), contract manufacturing organizations (CMOs), and companies that provide tools for research and development. Similar trends have been observed for companies that manufacture tools for production in the pharmaceutical and biotech industries. While these sectors have had ups and downs in the past two years, the trends are starting to normalize now. Hueffer was of the view that the industry is now showing considerable opportunity. The Fed\u2019s Rate Cuts and Biotech Stocks: Could There Be a Connection? Similarly, Goldman Sachs shed light on biotech as an often overlooked sector in the investing space. In a note to clients, John Flood, Goldman\u2019s Head of Americas Equities Sales Trading, said that biotech stocks posed an under-the-radar opportunity for investors looking to capitalize on the Fed\u2019s recent rate cuts. Changes in interest rates uniquely affect biotech stocks as they are sensitive to them and often rely on projected future profits. These stocks are also heavily impacted by the cost of capital. Although there is little to no current profitability, these stocks have significant upside potential and pose an \u201coption-like structure\u201d if clinical trials succeed. This makes them especially responsive to changes and movements in interest rates. Since September, the Fed cut a full point off the funds rate. According to CNBC, the current market pricing is showing just one or two more moves lower in 2025. On January 8, CNBC reported that the Federal Open Market Committee (FOMC) members voted to reduce the central bank\u2019s benchmark borrowing rate to the 4.25%-4.5% target range. However, they also slashed their outlook for expected rate cuts for 2025, bringing it down to two from four and assuming quarter-point increments. These changes are expected to affect biotech stocks. Story Continues Flood\u2019s note also highlighted that the biotech industry has recently shown improved fundamentals, attributed to a more favorable regulatory environment and positive clinical outcomes. Despite these tailwinds, Goldman\u2019s data reflects that biotechnology remains under-owned by hedge funds. The sector ranked in the 13th percentile in hedge fund long/short positioning over the past year. Furthermore, it ranked in the 4th percentile over the past five years. Our Methodology We used the Finviz stock screener to compile a list of 40 biotech stocks. We then selected the top 12 stocks with the highest analyst upside potential as of January 15, 2025. We have also included the market capitalization of the stocks as of the same date. The list is sorted in ascending order of analysts\u2019 average upside potential. These stocks are also popular among elite hedge funds, as of fiscal Q3 2024. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter\u2019s strategy selects 14 small cap and large cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points ( see more details here ). 12 Biotech Stocks with the Biggest Upside Potential A doctor and a patient discussing the success of the clinical trial for a new nonpeptide somatostatin receptor agonist. Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX ) Analyst Upside: 100.30% Number of Hedge Fund Holders: 37 Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is a clinical-stage pharmaceutical company that develops and commercializes novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company\u2019s product candidate, CRN00808, is an oral treatment for acromegaly. It is also developing other oral treatments for neuroendocrine tumors, hyperinsulinism, and Cushing\u2019s disease. On December 9, the company announced that the FDA accepted its New Drug Application (NDA) for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults. If approved, paltusotine would become the first and only once-daily oral treatment available for acromegaly in adults. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is thus preparing for the potential US launch of paltusotine. In addition, it is also building capabilities to commercialize paltusotine and support global clinical development of its other potential future drugs in the pipeline. The company plans to eventually bring paltusotine and its future drugs to European patients and expand its scope to the rest of the world. These expansion programs position the company for long-term success and profitability. Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is also introducing a new technology, non-peptide drug conjugates (NDCs), developed in-house through its drug discovery capabilities in G protein-coupled receptors (GPCRs). This novel platform selectively targets anti-tumor agents by leveraging endocrine receptors to treat the underlying tumors. If successful, the company\u2019s NDC platform might be applicable to a range of different cancers, which reflects its long-term potential. Overall, CRNX ranks 6th on our list of the 12 biotech stocks with the biggest upside potential. While we acknowledge the potential of biotech stocks, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than CRNX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock . READ NEXT: 20 Best AI Stock To Buy Now and 30 Most Important AI Stocks According to BlackRock . Disclosure: None. This article is originally published at Insider Monkey . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2025-01-17T19:12:22", "sentiment": {"score": 0.225076325237751, "confidence": 0.32594138383865356, "probabilities": {"positive": 0.32594138383865356, "negative": 0.10086505860090256, "neutral": 0.5731936097145081}}, "embedding": [-0.0650448128581047, -0.11459218710660934, -0.03926854580640793, -0.1210002452135086, 0.038711681962013245, 0.005316786468029022, -0.05401235073804855, 0.16764025390148163, 0.10095217823982239, 0.04309132695198059, -0.16335216164588928, 0.09817619621753693, -0.019582247361540794, 0.04918370395898819, -0.09562411159276962, -0.0500241294503212, -0.07702569663524628, 0.002610292285680771, -0.06405617296695709, 0.10027126967906952, -0.0651819109916687, -0.05770797282457352, 0.02533477544784546, 0.04725349694490433, -0.01810838095843792, -0.007235066033899784, 0.023067772388458252, -0.05331682413816452, -0.22949224710464478, 0.0031521343626081944, -0.02022850327193737, 0.1988542079925537, 0.08669251203536987, -0.06106771528720856, 0.02992418222129345, 0.1398543417453766, -0.031209591776132584, 0.10312920808792114, 0.10164225101470947, 0.027819456532597542, -0.03519096225500107, -0.03682321310043335, -0.0922902449965477, 0.04268971085548401, 0.11941701918840408, -0.19236299395561218, 0.043983105570077896, -0.09631052613258362, 0.06210523843765259, 0.01905713602900505, -0.16877427697181702, -0.15691548585891724, -0.0032409392297267914, 0.07684414088726044, -0.0806196853518486, 0.08392053097486496, -0.12837089598178864, -0.023961160331964493, 0.0716710090637207, 0.016247857362031937, 0.069595105946064, -0.04908047616481781, 0.06440067291259766, -0.009952476248145103, 0.11191865801811218, -0.05801317095756531, 0.025858523324131966, 0.07362217456102371, -0.07491990923881531, 0.05399511009454727, 0.12390521168708801, -0.09861668199300766, -0.12150435149669647, -0.058877382427453995, 0.007096655201166868, 0.10425401479005814, 0.10898405313491821, 0.22289767861366272, 0.18498015403747559, -0.1531103104352951, 0.11324052512645721, -0.05593080073595047, -0.0021928357891738415, -0.05448523536324501, -0.11909572780132294, 0.03160644695162773, 0.10823909193277359, 0.0053836507722735405, 0.09896954894065857, 0.023037757724523544, 0.02971733547747135, -0.035142384469509125, 0.04273434355854988, -0.035681627690792084, -0.0382002629339695, 0.0048408471047878265, -0.11482255160808563, 0.054126329720020294, 0.09325888752937317, -0.03874019533395767, 0.11501000821590424, 0.04856833815574646, -0.14606733620166779, 0.023195229470729828, -0.0674223080277443, -0.07308346033096313, -0.012590878643095493, -0.004593446850776672, 0.13858123123645782, 0.12709146738052368, -0.10591749846935272, 0.1950986683368683, -0.09502289444208145, -0.0434613972902298, -0.12320992350578308, 0.09099773317575455, -0.06523722410202026, -0.016928652301430702, 0.15347325801849365, -0.0034376811236143112, -0.02676534652709961, 0.08392978459596634, -0.18242451548576355, -0.172800213098526, 0.009373738430440426, 0.05159255117177963, -0.2160969227552414, 8.961302572308998e-33, -0.027222273871302605, 0.06818880140781403, 0.05090634897351265, -0.026369089260697365, -0.06132911890745163, 0.006338194943964481, -0.03769440948963165, -0.012706140987575054, -0.141390860080719, -0.10898823291063309, -0.21076688170433044, 0.10460029542446136, -0.0719752162694931, -0.005107778590172529, -0.05746924877166748, -0.1807079017162323, -0.0957040786743164, -0.04034653678536415, 0.07571253180503845, -0.019903186708688736, -0.20054616034030914, 0.056663066148757935, -0.06678374856710434, 0.0872754231095314, 0.030401386320590973, -0.10002410411834717, -0.08296077698469162, 0.019184496253728867, -0.028615441173315048, 0.049137283116579056, -0.004159859847277403, 0.08554107695817947, -0.013544888235628605, -0.08073145151138306, -0.027273457497358322, -0.048219889402389526, -0.009102638810873032, -0.08698193728923798, 0.024670181795954704, 0.06600312888622284, -0.09172840416431427, 0.16264158487319946, -0.1530998945236206, -0.08643496036529541, 0.05688922852277756, 0.08572706580162048, -0.020193949341773987, 0.03136845678091049, -0.015192929655313492, -0.02999984845519066, -0.16649186611175537, 0.0825779065489769, 0.13249561190605164, -0.0633801594376564, 0.02246905490756035, 0.003863806137815118, -0.16136062145233154, -0.12813344597816467, -0.002060098573565483, 0.15210014581680298, -0.010950908064842224, 0.14077641069889069, -0.005872474052011967, 0.1680302619934082, -0.1676640510559082, 0.20170515775680542, 0.024829275906085968, 0.07431358844041824, -0.060919828712940216, 0.21903589367866516, -0.03583080694079399, -0.05734476447105408, 0.0028690285980701447, -0.05567065626382828, 0.03523913770914078, -0.04208310693502426, -0.08000686764717102, 0.057114094495773315, -0.0377097949385643, 0.12829799950122833, 0.09825600683689117, -0.012345708906650543, -0.01875658705830574, -0.00692762341350317, -0.013131016865372658, -0.08185940235853195, 0.057355981320142746, 0.013406474143266678, 0.06898267567157745, 0.07219089567661285, -0.05313076078891754, -0.07530602067708969, -0.0017118528485298157, 0.22609665989875793, 0.011280817911028862, -1.0094875121161116e-32, 0.029332464560866356, -0.08266202360391617, -0.011179271154105663, 0.004374600015580654, -0.08414518088102341, 0.030600687488913536, 0.1147279143333435, -0.1227799654006958, 0.04104239493608475, -0.11983922123908997, 0.07320433855056763, 0.0718996673822403, -0.06299243867397308, 0.021895136684179306, -0.11623266339302063, -0.006183350458741188, -0.04786938801407814, -0.0739709883928299, -0.014158676378428936, 0.007824108935892582, 0.010377608239650726, 0.11624812334775925, -0.17645299434661865, 0.0767277181148529, -0.010327966883778572, 0.1366768777370453, -0.09589213132858276, 0.14729902148246765, 0.03388199955224991, -0.0075850095599889755, -0.10593981295824051, -0.0371180921792984, -0.18100541830062866, 0.1546243578195572, -0.050007447600364685, 0.042853664606809616, 0.02948123589158058, -0.1137591004371643, 0.09361070394515991, -0.01701650395989418, 0.142464280128479, 0.02850915864109993, -0.06764687597751617, 0.02594032883644104, 0.038248222321271896, -0.013393777422606945, -0.03610584884881973, 0.11813247203826904, 0.12789314985275269, 0.010485904291272163, -0.07198300957679749, 0.07497279345989227, 0.01570979319512844, -0.003261817153543234, -0.03219553083181381, 0.025143012404441833, -0.02467312105000019, 0.026202432811260223, -0.03351796045899391, 0.10737442225217819, 0.08340328931808472, 0.1114058867096901, 0.03784721717238426, 0.014690355397760868, -0.005137689411640167, 0.06191083788871765, 0.10069146752357483, -0.015628885477781296, -0.014804894104599953, -0.11310482025146484, 0.11354158818721771, -0.039179056882858276, 0.03323005139827728, -0.0543130524456501, -0.052423350512981415, 0.21016225218772888, -0.09561005234718323, -0.17469778656959534, -0.2348385751247406, 0.1075676754117012, 0.09268894046545029, 0.009516434744000435, 0.01911238767206669, 0.02725658193230629, -0.08195125311613083, 0.15923640131950378, -0.04037124291062355, -0.0890100821852684, -0.056910570710897446, -0.0694478452205658, -0.05903676152229309, -0.2130330502986908, -0.045740194618701935, 0.11065004765987396, -0.004507884383201599, -1.0050526810800875e-07, 0.06386372447013855, -0.17017030715942383, 0.03304009139537811, -0.13317005336284637, 0.06758362054824829, -0.10477228462696075, 0.01766936480998993, 0.006025619804859161, 0.16340544819831848, 0.2505103349685669, 0.048057250678539276, 0.12207522988319397, -0.15487349033355713, 0.14480680227279663, -0.05308982729911804, 0.0806848481297493, -0.1734716147184372, 0.045691635459661484, -0.026772094890475273, -0.043787017464637756, -0.038846712559461594, 0.10485866665840149, 0.04786673188209534, 0.03597567230463028, 0.10971896350383759, -0.11280961334705353, 0.04895680397748947, 0.011313153430819511, -0.022236160933971405, 0.05854179337620735, -0.03500692918896675, -0.047407686710357666, 0.18372032046318054, 0.03720329329371452, -0.014839363284409046, -0.06656281650066376, 0.0926104187965393, 0.03916853293776512, -0.01444509718567133, 0.031231336295604706, -0.04152597859501839, -0.037529006600379944, -0.1127202957868576, -0.03976821154356003, -0.012358173727989197, -0.10171867907047272, -0.06577621400356293, 0.12024876475334167, 0.0669814944267273, -0.18519386649131775, 0.06647294014692307, 0.041786663234233856, 0.032905131578445435, -0.02461015060544014, -0.010472986847162247, 0.049154914915561676, -0.14091990888118744, -0.04613274335861206, -0.06893346458673477, -0.09873320162296295, -0.004809791222214699, -0.253803551197052, 0.2078816294670105, -0.008848974481225014], "changes": {"1wk": 3.85542838081772}}, {"text": "PREMIUM Crinetics Shares Fall After Reporting 'Positive' Phase 2 Results for Congenital Adrenal Hyperplasia Treatment MT Newswires Fri, Jan 10, 2025, 9:19 PM 1 min read In This Article: CRNX -3.75% Crinetics Pharmaceuticals (CRNX) shares were down more than 12% Friday after the company reported po PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2025-01-10T21:19:22", "sentiment": {"score": -0.9277758039534092, "confidence": 0.9367890954017639, "probabilities": {"positive": 0.009013291448354721, "negative": 0.9367890954017639, "neutral": 0.054197587072849274}}, "embedding": [-0.07414695620536804, -0.13213782012462616, 0.03003416210412979, 0.08885816484689713, 0.07981664687395096, -0.024773601442575455, -0.04903145879507065, 0.08338233828544617, -0.04541927948594093, -0.021388374269008636, 0.12695878744125366, 0.09451506286859512, 0.03489484265446663, 0.07656534016132355, -0.0759483128786087, -0.012726373970508575, -0.016710879281163216, -0.07931993901729584, 0.13442468643188477, 0.03429571911692619, -0.1737440973520279, -0.06395748257637024, 0.009086213074624538, 0.1085151955485344, 0.04425131157040596, 0.054360926151275635, -0.11850092560052872, 0.05084874853491783, 0.10216542333364487, 0.11390189826488495, -0.02382040210068226, -0.03731175884604454, 0.03316543623805046, -0.02619548700749874, -0.0007145850686356425, 0.01871853694319725, -0.03536199778318405, -0.030062217265367508, -0.10060206800699234, 0.06153053045272827, 0.06967581808567047, -0.0036464445292949677, -0.20544467866420746, 0.01303347758948803, 0.004516713786870241, -0.15401050448417664, 0.11464684456586838, -0.01362259779125452, 0.044449225068092346, 0.2025376856327057, -0.02032441645860672, -0.18354791402816772, 0.22325879335403442, 0.042359668761491776, -0.03334541246294975, 0.14393870532512665, -0.4159772992134094, -0.02461112104356289, 0.03356301784515381, 0.03441958129405975, -0.031135082244873047, 0.05252377688884735, -0.08676722645759583, -0.13765829801559448, 0.13205945491790771, 0.044067561626434326, 0.14369121193885803, 0.08013735711574554, 0.06109177693724632, 0.04108237847685814, 0.12667161226272583, 0.09153115004301071, 0.07165008038282394, 0.02230086922645569, -0.03041396476328373, 0.28532594442367554, 0.008716939017176628, -0.14276058971881866, 0.05806756764650345, -0.13423487544059753, -0.1606869399547577, 0.0022501335479319096, -0.05118923634290695, -0.02169105038046837, 0.02004815824329853, 0.02391904778778553, 0.1915665566921234, -0.07806941866874695, -0.08049491047859192, -0.1825493574142456, 0.1263819932937622, 0.1029159277677536, 0.11423437297344208, -0.028566425666213036, -0.0014889491721987724, 0.038595471531152725, -0.14185135066509247, -0.02794887311756611, -0.07263883948326111, -0.017859064042568207, -0.034132927656173706, 0.181621715426445, -0.04520423337817192, -0.049937210977077484, -0.04343865439295769, -0.19975751638412476, 0.04669869691133499, 0.1521887332201004, -0.030067812651395798, 0.06305451691150665, -0.04920387268066406, 0.13240395486354828, 0.12834593653678894, -0.06277281045913696, 0.004682366736233234, 0.21767082810401917, -0.21019679307937622, 0.013428614474833012, 0.16445408761501312, -0.030361752957105637, -0.04605335369706154, 0.11054572463035583, -0.23836860060691833, -0.07727808505296707, 0.17075049877166748, 0.06086267903447151, -0.006374819669872522, 1.4462926905476302e-32, -0.037109632045030594, 0.15139512717723846, 0.13724642992019653, 0.03371512144804001, -0.0033684929367154837, 0.12194617837667465, -0.017772989347577095, -0.10274449735879898, -0.051495932042598724, -0.20484574139118195, -0.2061627209186554, 0.08077296614646912, 0.05194753780961037, -0.06543310731649399, -0.2725467085838318, -0.27507075667381287, 0.03133963420987129, 0.06227105110883713, 0.11212604492902756, 0.053121548146009445, -0.0971948578953743, 0.14027445018291473, 0.006566599942743778, 0.025622129440307617, -0.19531607627868652, 0.014376839622855186, 0.08385711908340454, 0.09810232371091843, 0.07498994469642639, 0.08932845294475555, -0.05418096482753754, 0.11527549475431442, 0.07845160365104675, -0.1425187885761261, -0.13434018194675446, 0.10192438215017319, -0.010183877311646938, 0.049902189522981644, -0.062457434833049774, 0.004394821356981993, -0.03640780225396156, -0.015973227098584175, -0.11671070009469986, -0.011815435253083706, 0.015926135703921318, -0.1135149598121643, 0.01927873305976391, -0.11113639175891876, -0.018005121499300003, -0.1578325778245926, -0.03438517451286316, 0.1564822643995285, -0.16233110427856445, -0.017093151807785034, -0.12997178733348846, 0.015992412343621254, -0.21256385743618011, -0.19742362201213837, 0.05951397493481636, 0.014189714565873146, 0.28714069724082947, 0.07869026064872742, 0.02268826775252819, -0.052363321185112, -0.21309369802474976, 0.01824146695435047, -0.11022160202264786, -0.2626761794090271, -0.18376094102859497, 0.17265069484710693, 0.09323239326477051, -0.04808739200234413, 0.06498198211193085, -0.04799909144639969, 0.14027200639247894, -0.047377195209264755, -0.04139738529920578, 0.022675998508930206, 0.045419808477163315, -0.03142128512263298, 0.049468591809272766, -0.101471908390522, 0.18792594969272614, 0.11751370131969452, 0.1136433556675911, -0.11467967182397842, -0.054669324308633804, 0.08505085855722427, -0.042102981358766556, -0.006804501172155142, 0.13465245068073273, -0.133070707321167, -0.029333440586924553, 0.12037508934736252, 0.0016886329976841807, -1.417663966443735e-32, -0.12060564756393433, -0.03180183470249176, -0.0453949049115181, -0.043214913457632065, -0.20619893074035645, 0.07704351097345352, -0.08874853700399399, 0.08236855268478394, 0.05659078434109688, 0.10419821739196777, 0.20178687572479248, 0.044270873069763184, -0.27423524856567383, -0.05056794732809067, -0.06301798671483994, 0.1173148974776268, 0.08407001942396164, -0.1235642284154892, 0.09176871180534363, 0.00683913379907608, 0.09437257796525955, 0.1973828673362732, -0.021190134808421135, 0.3351198136806488, 0.15462571382522583, 0.0600212924182415, 0.19467030465602875, 0.1323748528957367, 0.2106602042913437, -0.025753332301974297, -0.12166715413331985, -0.06721602380275726, -0.23674918711185455, 0.06831982731819153, 0.03905310109257698, -0.051736123859882355, -0.01255178265273571, -0.00443614786490798, -0.04768682271242142, 0.008665317669510841, 0.04224824160337448, -0.09571988880634308, 0.026812661439180374, 0.1331917941570282, 0.15853585302829742, 0.03339671343564987, 0.11769270896911621, -0.008470626547932625, 0.07482311129570007, 0.10688061267137527, -0.061098456382751465, -0.04591064527630806, 0.12162993103265762, 0.0320717953145504, 0.05689642205834389, 0.036176279187202454, -0.15674404799938202, 0.07324624806642532, -0.10557001084089279, 0.13406820595264435, 0.002332102507352829, 0.03549119457602501, -0.29124462604522705, -0.02083575166761875, -0.00397269194945693, 0.06377439945936203, 0.029202472418546677, 0.1000012755393982, 0.24068933725357056, -0.04671685770153999, 0.025687307119369507, -0.003908318001776934, 0.08903850615024567, -0.2851320207118988, -0.008619889616966248, 0.1185620129108429, -0.12367350608110428, 0.030541548505425453, -0.1574951410293579, -0.0009684955002740026, 0.053969815373420715, -0.09872283786535263, 0.06752298772335052, 0.02913261391222477, -0.15563924610614777, 0.040597621351480484, 0.015601086430251598, -0.028277600184082985, -0.10523075610399246, 0.08649203181266785, -0.03230152279138565, -0.1292433887720108, -0.14725671708583832, 0.03523585945367813, 0.15643876791000366, -9.983730819840275e-08, 0.12645241618156433, -0.06196144223213196, 0.20701125264167786, -0.005893570836633444, 0.08384689688682556, -0.029297074303030968, 0.01480437908321619, 0.10238268971443176, 0.010777482762932777, 0.2009907066822052, -0.3100552558898926, -0.04539076238870621, 0.023101814091205597, -0.10897119343280792, -0.21814359724521637, 0.04607429727911949, -0.07142499089241028, 0.16777043044567108, -0.03020327351987362, -0.12389997392892838, -0.11130498349666595, -0.02540147677063942, 0.16467322409152985, 0.04772568121552467, -0.08948802202939987, -0.051439106464385986, 0.12453743070363998, 0.03474331647157669, -0.16500696539878845, -0.06451921910047531, 0.06755751371383667, -0.12175503373146057, 0.011051692999899387, -0.006505939178168774, -0.07854467630386353, -0.0017972550122067332, 0.12763482332229614, 0.1436973363161087, 0.033295292407274246, 0.008891984820365906, -0.1467062383890152, -0.06419077515602112, 0.11337614804506302, 0.007170530501753092, 0.02331685833632946, -0.04444202035665512, -0.1380092054605484, 0.014846201054751873, 0.20371116697788239, -0.19698350131511688, 0.10215586423873901, -0.01902129128575325, 0.005793667398393154, -0.06126568093895912, -0.07933986932039261, 0.024757323786616325, -0.14715754985809326, -0.2094503939151764, -0.13931311666965485, -0.008742163889110088, -0.053988050669431686, -0.1457928568124771, -0.07390593737363815, 0.11533261090517044], "changes": {"1wk": -7.982265745964094}}, {"text": "Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Crinetics Pharmaceuticals, Inc. Sat, Jan 11, 2025, 1:15 AM 2 min read In This Article: CRNX -3.75% Crinetics Pharmaceuticals, Inc. SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on January 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggregate of 96,100 shares of its common stock to sixteen new non-executive employees and 100,000 to one new executive employee under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the \u201c2021 Inducement Plan\u201d). The stock options were granted as inducements material to the employees entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). The 2021 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Crinetics, or following a bona fide period of non-employment, as an inducement material to such individuals\u2019 entering into employment with Crinetics, pursuant to Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $40.59 per share, which is equal to the closing price of Crinetics\u2019 common stock on The Nasdaq Global Select Market on January 10, 2025. The shares subject to the stock options will vest over four years, with 25% of the shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the shares vesting in a series of 36 successive equal monthly installments thereafter, subject to each employee\u2019s continued employment with Crinetics on such vesting dates. The options are subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the grant. About Crinetics Pharmaceuticals Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics\u2019 lead development candidate, paltusotine , is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant , an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing\u2019s disease. All of the company\u2019s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves\u2019 disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Story Continues Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@crinetics.com (858) 345-6340 Media: Natalie Badillo Head of Corporate Communications nbadillo@crinetics.com (858) 450-6464 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2025-01-11T01:15:00", "sentiment": {"score": 0.020078604109585285, "confidence": 0.035315871238708496, "probabilities": {"positive": 0.035315871238708496, "negative": 0.015237267129123211, "neutral": 0.9494468569755554}}, "embedding": [-0.06448167562484741, -0.03951822593808174, 0.025617998093366623, -0.15404854714870453, -0.07350475341081619, 0.08471812307834625, 0.05147262662649155, 0.14198464155197144, 0.08422879129648209, 0.09712789952754974, -0.007480882108211517, 0.013327371329069138, 0.06668470799922943, 0.08211010694503784, -0.10971393436193466, 0.037936531007289886, -0.03989898040890694, -0.05270308256149292, -0.044788870960474014, 0.03615556284785271, -0.056395553052425385, 0.024617472663521767, -0.05256160348653793, 0.006009724456816912, -0.013613606803119183, -0.054149873554706573, -0.017415083944797516, 0.061792030930519104, -0.10014250874519348, 0.06342566013336182, 0.042838647961616516, 0.14445973932743073, 0.053598590195178986, -0.1069590300321579, -0.03525274246931076, 0.05601540580391884, -0.1604004055261612, 0.06452546268701553, 0.006239322945475578, 0.0809534564614296, -0.09397522360086441, -0.028852637857198715, -0.08171093463897705, 0.11158892512321472, 0.022144746035337448, -0.15504515171051025, 0.0015872325748205185, 0.03966866433620453, 0.010829810053110123, 0.13428953289985657, -0.057209134101867676, -0.03875564783811569, -0.006133937276899815, 0.11605793237686157, -0.12254901975393295, 0.037173621356487274, -0.25988107919692993, 0.020680811256170273, 0.07054851204156876, 0.015010087750852108, -0.042763154953718185, -0.029609307646751404, 0.026077548041939735, -9.515322744846344e-05, 0.12838993966579437, 0.06273389607667923, 0.057812388986349106, -0.017746005207300186, 0.03243239223957062, 0.020934822037816048, 0.12982186675071716, -0.08506874740123749, -0.022423824295401573, -0.06391680985689163, -0.06326883286237717, 0.17232833802700043, 0.06693446636199951, 0.07347190380096436, 0.06829039007425308, -0.23643943667411804, -0.07041015475988388, -0.04282008111476898, 0.011349530890583992, -0.06364528834819794, -0.0167827308177948, 0.07753860950469971, 0.05435700714588165, 0.10269354283809662, 0.17850103974342346, 0.008599378168582916, 0.09535734355449677, -0.0503961518406868, -0.0328206829726696, -0.14971499145030975, -0.029979916289448738, -0.057251445949077606, -0.08536574989557266, 0.020611640065908432, -0.03570607677102089, 0.032516323029994965, 0.05993203446269035, 0.009057458490133286, -0.15247562527656555, -0.03983714431524277, -0.0759076476097107, -0.10008707642555237, 0.07432644069194794, -0.04132634401321411, -0.040098950266838074, -0.04807892441749573, -0.2031192183494568, 0.08904307335615158, 0.017346739768981934, -0.07497479766607285, -0.07056411355733871, 0.20111583173274994, -0.05264176428318024, 0.009613661095499992, 0.2073565125465393, -0.04307819902896881, 0.08466741442680359, 0.050041764974594116, -0.0705886036157608, -0.12563665211200714, -0.02216164767742157, -0.06741500645875931, -0.12560151517391205, 1.2712510022610342e-32, -0.0455915741622448, 0.046811752021312714, 0.1218666285276413, 0.01746046356856823, -0.0344473198056221, -0.008724969811737537, 0.0010811509564518929, 0.050284530967473984, -0.1463170200586319, -0.05408761650323868, -0.21110883355140686, 0.08182545006275177, 0.034460585564374924, -0.01591932773590088, 0.008304819464683533, -0.10798852145671844, -0.013011466711759567, 0.04759145528078079, 0.09071680903434753, -0.020624518394470215, 0.008303109556436539, 0.10970137268304825, -0.05777573585510254, 0.1321873813867569, -0.006034226156771183, -0.004647203255444765, -0.017330843955278397, 0.05174699425697327, -0.014192469418048859, 0.023210372775793076, 0.03491821140050888, 0.09398934245109558, 0.08809418976306915, -0.08587945997714996, -0.019838757812976837, -0.009798798710107803, -0.11713685095310211, -0.05025572329759598, 0.05761469155550003, -0.020600300282239914, 0.055624768137931824, 0.03789513558149338, -0.010201874189078808, -0.11434383690357208, 0.037826284766197205, -0.09251685440540314, 0.0035541937686502934, 0.07582123577594757, 0.005292755551636219, 0.0606895312666893, 0.005093837156891823, 0.0713406354188919, 0.03007396310567856, -0.08521535992622375, -0.1303633451461792, -0.04139186441898346, -0.17744162678718567, -0.053602591156959534, 0.0845867246389389, 0.11349153518676758, 0.01598622463643551, 0.15965235233306885, -0.03076140210032463, 0.05628678947687149, -0.16630598902702332, 0.13135896623134613, -0.10560292750597, -0.21006621420383453, 0.10094691067934036, 0.10323579609394073, -0.01781388372182846, 0.02787395566701889, 0.11293365061283112, 0.010565459728240967, 0.12598687410354614, -0.07430878281593323, 0.028475942090153694, 0.012689498253166676, 0.017582159489393234, 0.008270212449133396, 0.0026797670871019363, -0.09485744684934616, -0.04398592188954353, 0.09030938148498535, 0.13329097628593445, -0.08365748822689056, 0.020002074539661407, 0.014382675290107727, 0.0019804462790489197, -0.01357283815741539, 0.1534005105495453, -0.11239279806613922, -0.054726045578718185, 0.19149458408355713, 0.08146454393863678, -1.0666528309541564e-32, -0.04021741449832916, -0.06315258890390396, -0.033479902893304825, -0.018041005358099937, 0.008960165083408356, 0.13671469688415527, 0.13358184695243835, -0.11779450625181198, 0.07546047121286392, -0.10926207900047302, 0.0843719020485878, 0.05184449255466461, 0.022560764104127884, -0.05517096072435379, -0.11894385516643524, 0.029241671785712242, -0.022091196849942207, -0.10644086450338364, -0.057789746671915054, 0.03452599048614502, 0.04082006588578224, 0.20704936981201172, -0.05046727508306503, 0.13591542840003967, 0.1416243016719818, 0.11891710758209229, 0.06711751967668533, 0.1616073101758957, 0.07426966726779938, 0.07314316928386688, -0.12542469799518585, -0.057317622005939484, -0.28113406896591187, 0.07307121157646179, 0.012038390152156353, -0.12692296504974365, 0.12291993200778961, -0.07202735543251038, 0.029217539355158806, -0.012465476989746094, 0.07982847094535828, -0.04701484739780426, 0.07140600681304932, 0.13997149467468262, 0.03658726066350937, -0.06140666455030441, 0.08442743122577667, -0.03827483206987381, 0.09061342477798462, -0.04970013350248337, -0.07817728072404861, -0.011028378270566463, 0.053709786385297775, 0.03761639818549156, 0.11085756123065948, 0.05916278436779976, -0.07355276495218277, -0.04921574145555496, 0.10039965063333511, 0.006988827139139175, 0.11659122258424759, 0.08331423252820969, -1.1278316378593445e-05, -0.021663038060069084, 0.1347978264093399, -0.08429120481014252, -0.055093683302402496, 0.05503418669104576, 0.04770205542445183, -0.09766259789466858, -0.0739406868815422, -0.15439271926879883, 0.11384345591068268, -0.13183002173900604, -0.00886301789432764, 0.06722887605428696, 0.056262291967868805, -0.19465738534927368, -0.12961505353450775, 0.0030943143647164106, -0.06160634756088257, -0.030700281262397766, 0.040627412497997284, 0.13417713344097137, -0.04146500676870346, -0.0005778875201940536, -0.005136736668646336, -0.051733098924160004, 0.03138142079114914, 0.044136255979537964, -0.06616731733083725, -0.07887914031744003, -0.0031307674944400787, 0.11996380239725113, 0.03554801642894745, -1.000615128532445e-07, 0.10741099715232849, -0.05288480222225189, 0.08743225038051605, -0.07823289185762405, 0.12732961773872375, -0.06491450220346451, 0.002265120856463909, -0.0455838106572628, 0.07247702777385712, 0.08914550393819809, 0.007363974582403898, 0.07590491324663162, -0.03352237120270729, 0.010711835697293282, -0.175082266330719, 0.08954452723264694, -0.09614555537700653, 0.010045883245766163, -0.0866408497095108, -0.10997374355792999, -0.12382453680038452, -0.07189460098743439, -0.005920523311942816, -0.0005517831887118518, 0.022275321185588837, -0.07322609424591064, 0.029538217931985855, 0.0684875100851059, -0.038324303925037384, 0.05164407938718796, -0.00919739343225956, -0.06926725804805756, 0.15702778100967407, -0.005377051420509815, -0.045440495014190674, 0.012148268520832062, 0.037063971161842346, 0.11647982895374298, -0.03982933610677719, 0.036239150911569595, -0.022174380719661713, -0.029735904186964035, -0.032593902200460434, 0.0219342689961195, 0.029872439801692963, -0.11841380596160889, -0.20692461729049683, -0.021518943831324577, 0.01108641643077135, -0.1655774712562561, 0.11986085027456284, 0.035507626831531525, 0.014949878677725792, -0.027528591454029083, 0.07896758615970612, 0.06046323478221893, -0.0698961615562439, -0.1505041867494583, -0.014904497191309929, -0.11388322710990906, -0.06050385534763336, -0.09871453791856766, 0.0357854887843132, -0.0018981583416461945], "changes": {"1wk": -7.982265745964094}}, {"text": "Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) Crinetics Pharmaceuticals, Inc. Fri, Jan 10, 2025, 3:00 PM 5 min read In This Article: CRNX -3.75% Crinetics Pharmaceuticals, Inc. Substantial, Rapid and Sustained Statistically Significant Reductions of Key Biomarkers Achieved Across Doses, Including up to 80% Mean Reduction of Androstenedione Meaningful Improvements Demonstrated in Multiple Clinical Signs and Symptoms of CAH Affecting Patient Health Safety and Efficacy Data Support Initiation of Phase 3 Clinical Trial Management to Host Investor Conference Call Today at 8:30 AM ET SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing\u2019s syndrome. \u201cThese exciting results show atumelnant not only lowered key biomarkers, but also had a significant impact on the signs and symptoms of CAH that are important to the overall health of people living with this condition,\u201d said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. \u201cWe are eager to move forward with a global Phase 3 pivotal trial for adults in CAH, as we simultaneously prepare to start a Phase 2b/3 trial in pediatric patients this year. Our internally discovered pipeline now has two drug candidates with positive later stage data, and we look forward to\u00a0submitting INDs for four additional candidates now in first-in-human enabling studies, as we continue our strategy for building the premier global endocrine company.\u201d \u201cThere has been a long-standing interest in using a potent, selective antagonist of the ACTH receptor for the treatment of CAH and other diseases of ACTH excess, leading to the design of atumelnant by Crinetics scientists,\u201d said Dr. Alan Krasner, M.D., chief endocrinologist of Crinetics. \u201cThis Phase 2 study demonstrated that atumelnant was well tolerated and resulted in a reduction of adrenal androgen levels so rapid and robust that it allowed patients to realize meaningful improvements in long-term, pre-existing medical challenges, even within the short 12-week treatment period of this study.\u201d Highlights from the Phase 2 TouCAHn Trial The TouCAHn trial is an open-label, global, Phase 2 study designed to evaluate the efficacy, safety, and pharmacokinetics of atumelnant when administered for 12 weeks in people with CAH caused by 21-hydroxylase deficiency. The study enrolled 28 patients across 3 dose cohorts with classic CAH on a stable dose of glucocorticoid replacement. Story Continues Primary endpoints included change from baseline in morning serum androstenedione (A4) levels and incidence of treatment-emergent adverse events. Change from baseline in morning serum 17-hydroxyprogesterone (17-OHP) was also evaluated as a secondary endpoint. Results For all doses, treatment with atumelnant resulted in rapid, substantial and sustained statistically significant reduction in A4 levels, the key biomarker for disease control (results in chart below). Primary Endpoint Atumelnant, Dosed Once Daily Mean A4 Baseline* (ng/dL) A4 Change from Baseline at Week 12 (ng/dL)** 40 mg (n=11) 1,213 -619 (p=0.0003) 80 mg (n=11) 1,231 -774 (p<0.0001) 120 mg (n=6) 1,064 -954 (p<0.0001) *Morning serum levels **Least square mean change Additionally, rapid, substantial and sustained statistically significant reductions in 17-OHP, a confirmatory secondary biomarker of disease control, were achieved across doses. Treatment with atumelnant also had a significant impact on CAH signs and symptoms, including: Substantial reduction and normalization of testosterone in the majority of female participants (8/13), 1 with 6 of the 11 impacted participants resuming menses Consistent reduction in total adrenal volume observed across dose cohorts Resolution of androgen mediated polycythemia in 5 of the 6 impacted participants Atumelnant has been generally well tolerated with no treatment-related severe or serious adverse events to date, irrespective of disease severity or dose level. No participants required dose reduction or discontinued from the trial. All adverse events to-date have been mild to moderate and generally transient. No consistent clinically important trends were observed across key safety parameters, including clinical safety laboratory values, physical examination, electrocardiogram or vital signs. The most common treatment-emergent adverse events included headache (7/28) and fatigue (5/28). Conference Call and Webcast Crinetics will host an investor conference call on January 10, 2025, at 8:30 am Eastern Time to discuss the topline results from this study. Following the live event, a replay will be available on the Investors section of the Company\u2019s website. Dial-in Details: Domestic: 1-800-445-7795 International: 1-785-424-1699 Conference ID: CRNXQ4 Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1703675&tp_key=d409cb44ff ABOUT ATUMELNANT Atumelnant, Crinetics\u2019 second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal gland. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data from a 12-week Phase 2 study demonstrated compelling treatment benefits of atumelnant, evidenced by the rapid, substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing\u2019s syndrome. For more information about the Phase 2 TouCAHn study in classic CAH, please visit clinicaltrials.gov ( NCT05907291 ). ABOUT\u00a0CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics\u2019 lead development candidate, paltusotine , is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Atumelnant is currently in development for congenital adrenal hyperplasia and ACTH-dependent Cushing\u2019s syndrome. All of the company\u2019s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves\u2019 disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant, including the therapeutic potential and clinical benefits or safety profile thereof; the expected timing of additional data and topline results from studies of atumelnant in CAH and ACTH-dependent Cushing\u2019s syndrome ; the expected timing and initiation of Phase 3 studies of atumelnant in CAH; the therapeutic potential and clinical benefits or safety profile of paltusotine; and the future development and focus of Crinetics . In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201cupcoming\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, initial or topline data that we report may change following completion or a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, and the FDA and other regulatory authorities may not agree with our interpretation of such results; unexpected adverse side effects or inadequate efficacy of the company\u2019s product candidates that may limit their development, regulatory approval and/or commercialization; clinical studies and preclinical studies may not proceed at the time or in the manner expected, or at all; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics\u2019 drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the company\u2019s periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company\u2019s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading \u201cRisk Factors\u201d in Crinetics\u2019 periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023 and its Quarterly report on Form 10-Q for the quarter ended March 31, 2024, June 30, 2024, and September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contact: Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@crinetics.com (858) 345-6340 Media: Natalie Badillo Head of Corporate Communications nbadillo@crinetics.com (858) 345-6075 1 Sample size includes female participants not on hormonal contraceptives with intact uterus. Those with restored menses following atumelnant treatment included three previously amenorrheic participants and three with previously irregular menses. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2025-01-10T15:00:00", "sentiment": {"score": 0.8603915004059672, "confidence": 0.8717349767684937, "probabilities": {"positive": 0.8717349767684937, "negative": 0.011343476362526417, "neutral": 0.1169215515255928}}, "embedding": [-0.05554240196943283, -0.11403286457061768, -0.03198416531085968, 0.02013484388589859, 0.0027408022433519363, -0.029353711754083633, -0.1343831717967987, 0.1865169107913971, 0.044414062052965164, 0.0939546450972557, -0.028723303228616714, -0.010877957567572594, -0.040023453533649445, 0.05269563943147659, -0.01454387791454792, 0.111204594373703, -0.006736861541867256, 0.027990983799099922, 0.0755249634385109, 0.00773656228557229, 0.04216259717941284, -0.013508815318346024, 0.03007569909095764, 0.10815171897411346, -0.06571857631206512, -0.011809935793280602, -0.15064607560634613, 0.047981470823287964, -0.14166203141212463, 0.05010991171002388, -0.027811959385871887, 0.11346552520990372, 0.05790456011891365, -0.028823256492614746, 0.00808357447385788, 0.07575203478336334, -0.09029404073953629, 0.033468425273895264, -0.09259523451328278, -0.018564287573099136, 0.01442079246044159, -0.07221908867359161, -0.13154016435146332, -0.01023201085627079, 0.038371920585632324, -0.1733141839504242, -0.04072466865181923, 8.34241509437561e-05, -0.0038226195611059666, 0.14599473774433136, -0.034083664417266846, -0.07308439910411835, 0.13399651646614075, 0.14562441408634186, -0.03744299337267876, 0.029075900092720985, -0.1935105323791504, 0.023499779403209686, -0.01568860188126564, 0.058590881526470184, -0.10157149285078049, 0.01712222211062908, -0.11832466721534729, -0.12904375791549683, 0.15229400992393494, 0.06336754560470581, 0.03207775205373764, -0.10878853499889374, 0.07062055170536041, -0.0019805561751127243, 0.048053205013275146, -0.008112156763672829, 0.11560624837875366, 0.05179430916905403, 0.04313287511467934, 0.0684560239315033, 0.022216202691197395, 0.04587738960981369, 0.07296790182590485, -0.1307905614376068, 0.0510067380964756, 0.11361229419708252, -0.04073840379714966, -0.058557964861392975, 0.009311338886618614, 0.03976573795080185, 0.02413385547697544, 0.09075308591127396, -0.027155518531799316, -0.024523017928004265, 0.06180218607187271, -0.03394727408885956, 0.007205821108072996, -0.00658738799393177, 0.13130584359169006, 0.014212206937372684, -0.11295630037784576, -0.0290457084774971, 0.008626225404441357, -0.09913773089647293, -0.023822957649827003, 0.05677931755781174, -0.09598013758659363, -0.031305618584156036, -0.010527781210839748, -0.041283898055553436, 0.022089798003435135, -0.0674690306186676, -0.07662399858236313, -0.01904517225921154, -0.04712120071053505, 0.030161898583173752, 0.0858415737748146, -0.010557723231613636, 0.03271859139204025, 0.1777324676513672, -0.11618161201477051, 0.03754296153783798, 0.14864972233772278, -0.06400995701551437, 0.055171068757772446, -0.051851894706487656, -0.0888916477560997, -0.0978466272354126, 0.1438823640346527, 0.08377266675233841, -0.04261043667793274, 1.2734631356924879e-32, 0.012062176130712032, 0.09000644832849503, 0.04149880260229111, 0.04638911783695221, 0.014089713804423809, 0.1127273440361023, 0.007437002379447222, 0.006552176550030708, -0.07418833673000336, -0.06598640978336334, -0.057108841836452484, -0.07392154633998871, 0.040294893085956573, 0.05366078019142151, -0.09670479595661163, -0.1523282527923584, -0.02262776345014572, 0.007529642432928085, 0.06098739802837372, -0.03919340670108795, 0.0001437002792954445, 0.0850055068731308, 0.0016138572245836258, 0.003699779510498047, -0.07293646037578583, 0.038543425500392914, -0.01921134814620018, 0.11966200172901154, -0.028544707223773003, 0.035930849611759186, -0.06567826867103577, 0.00428678747266531, 0.05425059795379639, -0.048271432518959045, -0.16567501425743103, -0.04599188268184662, -0.0507880374789238, -0.05394520238041878, 0.004091470967978239, 0.1218312531709671, 0.035402312874794006, 0.09601891040802002, -0.006693953648209572, 0.02113724872469902, -0.004079876467585564, -0.063637875020504, -0.07281408458948135, -0.11570195853710175, 0.021048149093985558, 0.004616407677531242, 0.02700119838118553, 0.02337942086160183, -0.005449534393846989, -0.052684295922517776, -0.12627921998500824, 0.05760008469223976, -0.17672517895698547, -0.21553920209407806, -0.06611302495002747, 0.09243205189704895, 0.018100084736943245, 0.02162887156009674, -0.01680738665163517, 0.05621674656867981, -0.16520655155181885, -0.04112528637051582, 0.0025311866775155067, -0.11132244765758514, -0.11107881367206573, 0.11189596354961395, -0.020677901804447174, -0.044326912611722946, 0.127310648560524, 0.034102510660886765, 0.1066868007183075, -0.035124294459819794, 0.13633544743061066, 0.17775598168373108, -0.04619523882865906, -0.12399232387542725, -0.0255499966442585, -0.010719532147049904, -0.026622064411640167, 0.2258598506450653, 0.022350553423166275, -0.0896778255701065, 0.0005881942342966795, -0.04641195386648178, -0.09210403263568878, -0.06273812800645828, 0.08104057610034943, -0.09310145676136017, 0.01189463771879673, 0.13197490572929382, -0.032905083149671555, -1.3799455853353125e-32, -0.046161212027072906, -0.03999072313308716, -0.009240830317139626, -0.09888046979904175, -0.08672536909580231, 0.16306310892105103, 0.11098751425743103, -0.11159374564886093, 0.07020287960767746, -0.14167749881744385, 0.0574689656496048, 0.08739317208528519, -0.11835676431655884, -0.13539564609527588, -0.01569361612200737, 0.08306896686553955, -0.06749196350574493, -0.07204269617795944, 0.008580585941672325, 0.016777750104665756, 0.18160319328308105, 0.1263880729675293, -0.1280333399772644, 0.09514084458351135, 0.14164182543754578, -0.017389435321092606, 0.1509147584438324, 0.027199016883969307, 0.1179172694683075, 0.05677919089794159, -0.09081685543060303, 0.022563952952623367, -0.19006235897541046, -0.024046700447797775, 0.040239542722702026, -0.015113258734345436, 0.02605350688099861, -0.059181809425354004, -0.1353847086429596, 0.03043513186275959, -0.00617339089512825, 0.07182813435792923, -0.08769834041595459, 0.03005801886320114, 0.048925675451755524, 0.12761397659778595, 0.08848465234041214, 0.06580443680286407, 0.0333208292722702, 0.0225873701274395, -0.03594992309808731, -0.008373572491109371, 0.017285984009504318, -0.0451328307390213, -0.005974228493869305, 0.05753181874752045, -0.12726986408233643, -0.04982369393110275, -0.11326593160629272, 0.07942672073841095, -0.005623306147754192, 0.04902723804116249, -0.11408980190753937, -0.08973538875579834, 0.08966641128063202, 0.044980213046073914, 0.06531600654125214, -0.04678168147802353, 0.13075461983680725, -0.02383129671216011, -0.08160477131605148, -0.057352691888809204, 0.028984256088733673, -0.005637345835566521, -0.0012603899231180549, -0.054673463106155396, -0.10017599165439606, -0.11331434547901154, -0.09488014876842499, -0.010092489421367645, 0.00973915122449398, -0.006094587035477161, 0.03160957992076874, 0.06722255051136017, -0.019659914076328278, 0.09035567194223404, 0.008191761560738087, 0.0478379912674427, 0.007802692241966724, 0.03397409990429878, -0.039779193699359894, -0.002052726224064827, -0.20233142375946045, 0.04034847021102905, 0.09066469222307205, -1.0122586502347986e-07, 0.15332666039466858, -0.05417618900537491, 0.05125647038221359, -0.12498705089092255, -0.0497378408908844, -0.07511281967163086, 0.05330728739500046, 0.1131710633635521, -0.04421257600188255, 0.025945546105504036, -0.08575941622257233, 0.11258502304553986, 0.012241411954164505, -0.010818446055054665, -0.11657323688268661, 0.04825717955827713, 0.024112962186336517, 0.08121275901794434, -0.08646322786808014, 0.014467252418398857, -0.12220223248004913, -0.01913217268884182, -0.026420002803206444, -0.10619400441646576, 0.04369775205850601, -0.06103581190109253, 0.07116773724555969, 0.14869527518749237, -0.07608387619256973, -0.012257589027285576, 0.11109456419944763, -0.1346319019794464, 0.029148755595088005, 0.06451331079006195, 0.03706379979848862, -0.061949580907821655, -0.01637105830013752, 0.09994343668222427, -0.012836219742894173, 0.06777064502239227, -0.0017524920403957367, 0.016410596668720245, 0.059271108359098434, 0.07114731520414352, -0.00013482477515935898, -0.16446492075920105, -0.11789026856422424, 0.009926984086632729, 0.16467000544071198, -0.06582677364349365, -0.07266834378242493, 0.05719463899731636, -0.019522957503795624, -0.07059185206890106, 0.04390919953584671, 0.08066186308860779, -0.10110415518283844, -0.10311724245548248, 0.014333819039165974, -0.08033466339111328, 0.1617192029953003, -0.042899277061223984, -0.02105633355677128, 0.03064279817044735], "changes": {"1wk": -10.12564817664708}}, {"text": "Crinetics Pharmaceuticals to Participate in the 43rd Annual J.P. Morgan Healthcare Conference Crinetics Pharmaceuticals, Inc. Mon, Jan 6, 2025, 4:00 PM 1 min read In This Article: CRNX -3.75% Crinetics Pharmaceuticals, Inc. SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics, will present at the 43 rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Tuesday, January 14, 2025 at 4:30 p.m. Pacific Time. To access the live webcast, click here . The archived webcast will also be accessible on the Events & Presentations page in the Investors section of the Crinetics\u2019 website at www.crinetics.com/events . If you are interested in arranging a 1x1 meeting with management, please contact your conference representative. ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics\u2019 lead development candidate, paltusotine, is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing\u2019s disease. All of the company\u2019s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves\u2019 disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@crinetics.com (858) 345-6340 Media: Natalie Badillo Head of Corporate Communications nbadillo@crinetics.com (858) 345-6075 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2025-01-06T16:00:00", "sentiment": {"score": 0.12294607050716877, "confidence": 0.13184355199337006, "probabilities": {"positive": 0.13184355199337006, "negative": 0.008897481486201286, "neutral": 0.8592588901519775}}, "embedding": [-0.006956454366445541, -0.151718407869339, -0.1032404750585556, -0.09731984883546829, -0.013048080727458, 0.00580192357301712, -0.012650353834033012, 0.1873391568660736, 0.07917136698961258, 0.06385521590709686, -0.13324004411697388, 0.04299227148294449, 0.0692376047372818, 0.11952835321426392, -0.06537344306707382, 0.023266218602657318, 0.015803467482328415, -0.004301728680729866, 0.08179990947246552, 0.01992926560342312, -0.013063016347587109, 0.09392525255680084, 0.0709182396531105, 0.06262828409671783, -0.1563628911972046, 0.05546683818101883, -0.012413568794727325, -0.00818789191544056, -0.19030244648456573, 0.05470816045999527, 0.005706628784537315, 0.0758112296462059, 0.06472787261009216, -0.030391432344913483, 0.08024650812149048, 0.11532473564147949, -0.15933147072792053, 0.07044067978858948, -0.05291950702667236, 0.021512731909751892, -0.11070549488067627, -0.015231218189001083, -0.029941895976662636, 0.09738163650035858, -0.00899200327694416, -0.21560537815093994, -0.0674322098493576, 0.032248735427856445, -0.021858466789126396, 0.15042009949684143, -0.03915888071060181, -0.08763519674539566, 0.05378328636288643, 0.11535371840000153, -0.014338469132781029, 0.07981997728347778, -0.33571046590805054, 0.07160958647727966, 0.043078090995550156, -0.09616038203239441, -0.03849039599299431, 0.009787918999791145, 0.029737744480371475, -0.04699830710887909, 0.08613180369138718, 0.14581158757209778, 0.037958428263664246, -0.003920692950487137, 0.07026509940624237, -0.019656367599964142, 0.1228189542889595, -0.03298300504684448, 0.057494357228279114, -0.028657250106334686, 0.011219649575650692, 0.06954589486122131, 0.09563596546649933, 0.08242123574018478, 0.0529523640871048, -0.101727694272995, 0.03352823108434677, -0.028750859200954437, 0.0533425435423851, -0.0014568393817171454, -0.026327142491936684, 0.10653851926326752, 0.048169322311878204, 0.09811965376138687, 0.08520012348890305, -0.01665872521698475, 0.11614418029785156, 0.07812897861003876, -0.016158118844032288, -0.07917579263448715, -0.015287484973669052, -0.06924112141132355, -0.053227707743644714, 0.02161525934934616, 0.016609009355306625, -0.02469739131629467, -0.0065604643896222115, 0.06498809903860092, -0.08207663893699646, -0.005645718425512314, -0.03858838230371475, -0.05052872747182846, -0.004585062153637409, 0.04421118274331093, -0.036133769899606705, -0.03127152845263481, -0.19008001685142517, 0.08525820076465607, 0.02443789318203926, -0.04334143176674843, 0.06473860889673233, 0.2065279185771942, -0.025119900703430176, 0.098492830991745, 0.1763560026884079, 0.0060727596282958984, 0.03575888276100159, 0.06739011406898499, -0.04664205014705658, -0.1133996844291687, 0.09542152285575867, 0.06468989700078964, -0.13961012661457062, 1.3086533223258793e-32, -0.03229521960020065, 0.11939680576324463, 0.1517699658870697, -0.012172894552350044, 0.007605127990245819, 0.03076157718896866, 0.0019291909411549568, 0.02323393151164055, -0.11927425861358643, -0.13307815790176392, -0.1779463291168213, 0.0208283681422472, 0.09307089447975159, -0.002735218033194542, -0.09243549406528473, -0.17172756791114807, -0.013515247032046318, 0.029045790433883667, 0.050291791558265686, -0.1395987719297409, -0.06792829185724258, 0.07268787175416946, 0.0459689125418663, 0.14595043659210205, -0.07029683887958527, 0.04342484101653099, 0.031563568860292435, 0.2197973132133484, 0.08940599113702774, 0.018592089414596558, -0.09422476589679718, 0.05220630764961243, 0.07427565008401871, -0.0978877916932106, -0.06699339300394058, -0.012483302503824234, -0.10858654230833054, -0.1006745919585228, 0.027405675500631332, 0.026355218142271042, -0.043907180428504944, -0.008368287235498428, -0.08752939105033875, -0.03806833177804947, 0.05532731115818024, -0.14346502721309662, -0.02627541311085224, 0.03370329365134239, -0.007614567875862122, -0.07525976747274399, -0.01286633312702179, 0.0118994927033782, 0.017198044806718826, -0.04415266588330269, -0.031089916825294495, 0.011080026626586914, -0.13959649205207825, -0.11269646883010864, 0.09363046288490295, 0.1147485300898552, 0.05532773584127426, 0.07398486882448196, -0.05193474143743515, 0.02639748342335224, -0.048153702169656754, 0.009641310200095177, -0.09447945654392242, -0.1569572389125824, -0.05951012670993805, 0.09580858051776886, 0.03256138786673546, -0.004808603785932064, 0.16758574545383453, 0.08024737238883972, 0.18181365728378296, 0.006342827342450619, 0.02996978908777237, 0.09027078747749329, -0.021496262401342392, 0.029330961406230927, -0.08920475840568542, -0.07597595453262329, -0.06684866547584534, 0.18974569439888, 0.018867887556552887, -0.13945376873016357, 0.0015751919709146023, -0.029398389160633087, -0.034867726266384125, 0.059433698654174805, 0.0698276162147522, -0.13321155309677124, -0.05351017788052559, 0.1385703980922699, -0.004525832831859589, -1.023592489236819e-32, -0.05962836742401123, 0.015077264048159122, 0.010238045826554298, -0.00634158868342638, -0.04429687559604645, 0.09756834805011749, 0.07028833031654358, -0.1579538881778717, 0.18620643019676208, -0.15020368993282318, 0.08957516402006149, 0.07264808565378189, -0.09441179037094116, -0.16559387743473053, -0.09983786940574646, 0.078147292137146, 0.038723088800907135, -0.10668320953845978, -0.08474381268024445, 0.023174086585640907, 0.10133323073387146, 0.13240966200828552, -0.12543036043643951, 0.004477370996028185, 0.06108351796865463, 0.06437917053699493, 0.17259475588798523, 0.13229787349700928, 0.07300016283988953, 0.0648452490568161, -0.06516005098819733, 0.04086201265454292, -0.22079727053642273, 0.023428045213222504, -0.04144793376326561, 0.05084160342812538, -0.027737542986869812, -0.11179445683956146, 0.030276529490947723, -0.1071692705154419, 0.021464500576257706, -0.0354696549475193, -0.05357763543725014, 0.09759851545095444, 0.07996425032615662, 0.038442499935626984, 0.04081560671329498, 0.15659216046333313, 0.04753509908914566, 0.0034738413523882627, -0.15148811042308807, -0.004055986180901527, 0.00010158075019717216, -0.09061946719884872, 0.13587042689323425, 0.0672377496957779, -0.14521373808383942, -0.06191294267773628, 0.02424374409019947, 0.0415995717048645, 0.07648313790559769, 0.029869811609387398, -0.01081475242972374, 0.02465580403804779, 0.14044137299060822, -0.03503348305821419, 0.030968379229307175, 0.08875573426485062, 0.16018876433372498, -0.03022843971848488, -0.03125647455453873, -0.04548712447285652, 0.12233658879995346, 0.05540457367897034, -0.04435592517256737, -0.011970067396759987, -0.062416136264801025, -0.09942510724067688, -0.08515463769435883, -0.001044711098074913, 0.07113821804523468, -0.03037785366177559, 6.155949085950851e-05, 0.02403387241065502, 0.012904077768325806, 0.04184127599000931, 0.056012287735939026, -0.0246608667075634, 0.03735143318772316, 0.02846444584429264, -0.08720260858535767, -0.06360187381505966, -0.03923994302749634, 0.10317948460578918, 0.10471098124980927, -9.958453972558345e-08, 0.13262248039245605, -0.12332135438919067, 0.07264986634254456, -0.16201208531856537, 2.3569446057081223e-05, -0.0352771021425724, 0.020573126152157784, -0.0028812214732170105, -0.0037115290760993958, 0.0657895877957344, -0.1031930074095726, 0.05731328949332237, 0.0222516730427742, -0.039687760174274445, -0.1763889342546463, 0.08696205914020538, -0.056627824902534485, 0.03633074462413788, -0.1133345291018486, -0.07565511018037796, -0.15049883723258972, -0.05616886168718338, 0.01988278143107891, -0.026889141649007797, 0.10867013037204742, -0.1334618330001831, -0.010082976892590523, 0.07088534533977509, -0.07325715571641922, -0.02333916164934635, 0.011150626465678215, -0.09816647320985794, 0.1640450656414032, 0.0009929807856678963, 0.03335042670369148, -0.03404151275753975, -0.04970656335353851, 0.0867929682135582, 0.05641547963023186, 0.0938473790884018, -0.04986581951379776, 0.018262887373566628, -0.008966336026787758, 0.05002141743898392, -0.04762918874621391, -0.08208093047142029, -0.12196740508079529, 0.08100567758083344, 0.024361109361052513, -0.10767167806625366, -0.026969870552420616, 0.039464980363845825, -0.020311804488301277, -0.14899012446403503, -0.015034829266369343, 0.17769190669059753, -0.04307521879673004, -0.11534471809864044, 0.04657231643795967, -0.10221903026103973, -0.15294238924980164, -0.05293252319097519, 0.03527741879224777, 0.002942558377981186], "changes": {"1wk": -19.607845507561358}}, {"text": "Crinetics Pharmaceuticals Appoints Isabel Kalofonos as Chief Commercial Officer Crinetics Pharmaceuticals, Inc. Mon, Dec 16, 2024, 4:00 PM 4 min read In This Article: CRNX -3.75% Crinetics Pharmaceuticals, Inc. SAN DIEGO, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of Isabel Kalofonos as Chief Commercial Officer. Ms. Kalofonos will lead the company\u2019s commercial strategy and operations for the potential launch of paltusotine, the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist for adults living with acromegaly and will lead pre-commercialization activities for the company\u2019s deep, innovative pipeline of candidates. \u201cIsabel is a highly accomplished leader with broad commercial expertise ranging from launching therapies to leading early-stage commercial strategy,\u201d said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. \u201cHer expertise includes a proven track record of building and managing global commercial organizations, driving successful global launches of breakthrough therapies and bringing innovative medicines to market. I am thrilled to welcome Isabel into this pivotal commercial leadership role as we seek to deliver a new generation of therapy for acromegaly and transform the lives of large numbers of people impacted by other endocrine-related conditions.\u201d \u201cI feel so fortunate to join Crinetics at this time,\u201d said Ms. Kalofonos. \u201cBuilding highly effective commercial teams to launch transformative products has been the focus of my career. I look forward to bringing my experience to a company like Crinetics that is well-positioned to be a leader in endocrinology and has the potential to make a meaningful advancement for the acromegaly community and endocrine disorders. I look forward to leading the company\u2019s strategy for the first potential commercial launch, building a best-in-class commercial team and continuing to build value for products in the pipeline.\u201d Ms. Kalofonos joins Crinetics with more than 20 years of global experience in the pharmaceutical and biotech industry, including roles leading business and commercial units and expertise in marketing, new product planning, market access and pricing. She previously served as Senior Vice President and Chief Commercial Officer at ImmunoGen (acquired by Abbvie), where she was responsible for leading the successful launch of ELAHERE (mirvetuximab), a treatment for ovarian cancer and for overseeing the commercial strategy for the pipeline of antibody-drug conjugates in oncology indications. Ms. Kalofonos led the sales, marketing, market access and commercial operations teams in the U.S., as well as international launch preparation. Prior to ImmunoGen, Ms. Kalofonos worked at Galderma, where she served as Senior Vice President and Global Head of the Prescription Business Unit. During her tenure, she led the launch preparation for NEMLUVIO (nemolizumab), a monoclonal antibody for the treatment of atopic dermatitis and prurigo nodularis, as well as global market access, real-world evidence, pricing, and health economics and outcomes research. Prior to Galderma, Ms. Kalofonos held roles of increasing responsibility at Takeda Pharmaceuticals (formerly Shire), most recently serving as Vice President and Head of the Hereditary Angioedema (HAE) franchise, a $2.5-billion business. In this role, she oversaw the global blockbuster launch of TAKHZYRO (lanadelumab-flyo). Prior to the Takeda acquisition, Ms. Kalofonos held roles of increasing responsibility at Shire within corporate strategy, new product planning, and commercial, and gained experience across multiple therapeutic areas, including immunology, rare diseases, oncology, neurology, transplant, and gene therapy. Ms. Kalofonos holds an MBA in entrepreneurship and marketing from Babson College and an undergraduate degree in industrial engineering from Pontificia Universidad Javeriana. Story Continues On January 10, 2025, the Company expects to grant Ms. Kalofonos a stock option to purchase 100,000 shares of common stock under the Crinetics Pharmaceuticals, Inc. 2021 Employment Inducement Incentive Award Plan (the \u201c2021 Inducement Plan\u201d), 25 percent of which will vest on December 16, 2025, and the remainder will vest in 36 equal monthly installments thereafter. The stock option will have an exercise price equal to the closing price of the Company\u2019s common stock on the Nasdaq Global Select Market on January 10, 2025. The stock option will be subject to the terms and conditions of the 2021 Inducement Plan and the terms and conditions of a stock option agreement covering the respective grant. The stock option will be granted as an inducement material to Ms. Kalofonos entering into employment with Crinetics in accordance with Nasdaq Listing Rule 5635(c)(4). ABOUT CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics\u2019 lead development candidate, paltusotine , is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant, an investigational, first-in-class, oral ACTH antagonist that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing\u2019s disease. All of the company\u2019s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves\u2019 disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the, the therapeutic potential and clinical benefits or safety profile of paltusotine for patients with acromegaly, the plans and timelines for the commercial launch paltusotine for acromegaly, if approved, and the potential of our other research, discovery, and clinical trial programs. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201cupcoming\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, geopolitical events may disrupt Crinetics\u2019 business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; unexpected adverse side effects or inadequate efficacy of the Company\u2019s product candidates that may limit their development, regulatory approval and/or commercialization; the Company\u2019s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; regulatory developments in the United States and foreign countries; and Crinetics\u2019 drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company\u2019s periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company\u2019s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading \u201cRisk Factors\u201d in Crinetics\u2019 periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023, and its Quarterly reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024, and September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@crinetics.com (858) 345-6340 Media: Natalie Badillo Head of Corporate Communications nbadillo@crinetics.com (858) 345-6075 View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2024-12-16T16:00:00", "sentiment": {"score": 0.4099154341965914, "confidence": 0.4196178615093231, "probabilities": {"positive": 0.4196178615093231, "negative": 0.009702427312731743, "neutral": 0.5706796646118164}}, "embedding": [-0.052940044552087784, -0.19886066019535065, -0.05702824890613556, -0.056811463087797165, -0.056288979947566986, 0.026738205924630165, 0.04209452494978905, 0.19006367027759552, 0.062164947390556335, 0.08501557260751724, -0.13777375221252441, -0.03724651038646698, -0.0204564668238163, 0.10497356206178665, -0.09583113342523575, 0.07535934448242188, 0.02833028882741928, -0.053657591342926025, 0.02232029289007187, -0.029146701097488403, -0.020366594195365906, -0.03666266053915024, 0.07073797285556793, 0.08825771510601044, -0.1277340054512024, 0.05121150612831116, -0.08496251702308655, -0.06871698051691055, -0.1567082405090332, -0.05298398807644844, -0.035627108067274094, 0.10891308635473251, 0.13288936018943787, -0.05857544764876366, 0.031113121658563614, 0.1579471081495285, -0.14140944182872772, 0.06716272234916687, -0.09526233375072479, -0.017259644344449043, -0.02603650838136673, -0.03763480484485626, -0.10540390014648438, 0.04048831760883331, -0.0040576886385679245, -0.25966012477874756, -0.003225104184821248, 0.08187118172645569, 0.016998283565044403, 0.16468170285224915, -0.12355682998895645, -0.2244543582201004, 0.011292153969407082, 0.025607969611883163, -0.06013377755880356, 0.16810208559036255, -0.2640727758407593, 0.014976512640714645, 0.09158189594745636, 0.033546485006809235, -0.0013703941367566586, 0.031931497156620026, 0.01974579505622387, 0.05961427837610245, 0.08507810533046722, 0.022780023515224457, 0.04738646000623703, 0.0352863185107708, -0.0015710871666669846, -0.021856622770428658, 0.13304711878299713, -0.1257132738828659, 0.027673762291669846, 0.07456628978252411, 0.11755460500717163, 0.12150134146213531, 0.1382506638765335, 0.0763765424489975, 0.058558881282806396, -0.0757158175110817, 0.12685522437095642, 0.005682198330760002, 0.06347037106752396, -0.014166055247187614, -0.06436726450920105, 0.06089695915579796, -0.009282249957323074, -0.020243406295776367, 0.08351260423660278, 0.0008793016895651817, 0.08250617235898972, -0.004701775498688221, 0.06058774143457413, -0.09294425696134567, 0.0642828494310379, 0.026648595929145813, -0.04573687165975571, -0.029765896499156952, -0.0007237959653139114, 0.01999489963054657, -0.04666072875261307, 0.07294577360153198, -0.07475897669792175, -0.04296552762389183, -0.0686773732304573, -0.11636263877153397, 0.01160438358783722, -0.04858638346195221, 0.015235984697937965, 0.07960750162601471, -0.14337193965911865, 0.07009904086589813, -0.05848819017410278, -0.03525308892130852, 0.07625254988670349, 0.13547340035438538, -0.07029295712709427, 0.057090431451797485, 0.18677400052547455, -0.014543265104293823, 0.04728080704808235, 0.009420470334589481, -0.12470966577529907, -0.09424878656864166, 0.10403542220592499, 0.10775305330753326, -0.0457950197160244, 9.541224628763511e-33, -0.022136656567454338, 0.17018087208271027, 0.1696414202451706, 0.13333860039710999, 0.004089321009814739, 0.045808665454387665, -0.00536412512883544, 0.002121306024491787, -0.18825864791870117, -0.10104674100875854, -0.19701668620109558, 0.08736289292573929, 0.07033344358205795, 0.08237986266613007, -0.07673971354961395, -0.14860385656356812, -0.06321380287408829, -0.030625248327851295, 0.059096090495586395, 0.00763412332162261, -0.013411699794232845, 0.08200621604919434, -0.07490125298500061, 0.18091575801372528, -0.06833165884017944, 0.06739538162946701, 0.015156293287873268, 0.16390742361545563, 0.03670857474207878, 0.048264943063259125, -0.07952059805393219, 0.04840923845767975, 0.02563510462641716, -0.12038826942443848, -0.08292324841022491, -0.07101830840110779, -0.1121668890118599, -0.2341148555278778, -0.0037949811667203903, 0.04842720925807953, -0.05830242484807968, 0.04833494871854782, -0.06202111393213272, -0.041174426674842834, 0.007027588784694672, -0.12420149892568588, 0.034055713564157486, -0.02531534433364868, 0.0371384397149086, -0.024647308513522148, -0.03938693553209305, 0.03749798238277435, 0.06581239402294159, 0.026308001950383186, -0.04515741765499115, 0.06241483613848686, -0.11692584306001663, -0.10785438120365143, 0.073799267411232, 0.029931044206023216, 0.0247030146420002, 0.06340295076370239, -0.03372151777148247, 0.04858369380235672, -0.061030082404613495, -0.0024841059930622578, -0.002287329640239477, -0.14240175485610962, -0.0013967114500701427, 0.09149202704429626, -0.01969127729535103, -0.004601994529366493, 0.051298461854457855, 0.012378368526697159, 0.06345076858997345, 0.015295173041522503, 0.014563278295099735, 0.1713525652885437, -0.0693780928850174, 0.05408168211579323, 0.06067221984267235, 0.005534809082746506, 0.025656618177890778, 0.19110611081123352, 0.13660553097724915, -0.14383569359779358, -0.007001481484621763, -0.013985958881676197, -0.0039609214290976524, 0.07869729399681091, 0.06305821985006332, -0.038573432713747025, -0.030246175825595856, 0.17665521800518036, -0.041526682674884796, -9.053572266692824e-33, 0.030392896384000778, -0.07228278368711472, 0.07115287333726883, -0.015508431009948254, -0.019373461604118347, 0.09263499081134796, 0.055922433733940125, -0.12531545758247375, 0.1131044328212738, -0.179411381483078, 0.16097986698150635, 0.03109220787882805, -0.03683916851878166, -0.12054309248924255, -0.09684975445270538, 0.07274320721626282, 0.05310618877410889, -0.08636197447776794, -0.06302542239427567, -0.07591502368450165, 0.046456366777420044, 0.16265201568603516, -0.10506075620651245, 0.05249197408556938, 0.022588612511754036, 0.04937473684549332, 0.11889734864234924, 0.11814625561237335, 0.02412571758031845, 0.021414436399936676, -0.04520907625555992, -0.05692923441529274, -0.23633646965026855, -0.014461588114500046, -0.05616648495197296, 0.0402248315513134, -0.05325871706008911, -0.0730181485414505, -0.02617308497428894, -0.05860654264688492, 0.1419125199317932, 0.04864984005689621, -0.04656451568007469, -0.020042793825268745, 0.014193713665008545, 0.007430494762957096, 0.09306403994560242, -0.00321299210190773, 0.06973835825920105, -0.008472161367535591, -0.15528905391693115, -0.02218730002641678, -0.06809242069721222, -0.10068129003047943, 0.059682488441467285, 0.011317634955048561, -0.027023930102586746, -0.023270638659596443, 0.07208006829023361, -0.001641891896724701, 0.03500088304281235, 0.031557537615299225, 0.022597752511501312, -0.03972423076629639, 0.08978565782308578, 0.033445123583078384, 0.09375250339508057, 0.031224502250552177, 0.005206115543842316, -0.1061190515756607, -0.027715960517525673, -0.03229513391852379, -0.05056881532073021, -0.02911992557346821, -0.08929157257080078, -0.0261785127222538, -0.10931581258773804, -0.16143688559532166, -0.14477959275245667, -0.053813386708498, 0.02051599510014057, -0.1561882197856903, 0.021893737837672234, 0.06376051157712936, 0.0576736181974411, 0.08088061958551407, -0.018512770533561707, -0.07999983429908752, 0.03474893420934677, 0.09058567881584167, -0.05636320263147354, -0.1077590361237526, -0.05746793374419212, 0.052211642265319824, 0.11366183310747147, -1.0065146227589139e-07, 0.1051928699016571, 0.017065098509192467, 0.04063185676932335, -0.08505339175462723, 0.05362469702959061, -0.006803284864872694, -0.09857684373855591, -0.03248092532157898, 0.011657210998237133, 0.09906341135501862, -0.10357744991779327, 0.06952294707298279, 0.02737782709300518, 0.057917553931474686, 0.01909787952899933, 0.10678399354219437, -0.056970689445734024, 0.08453112840652466, -0.07595580816268921, -0.056847475469112396, -0.07191342860460281, 0.005535563454031944, -0.003785797394812107, -0.01832115277647972, 0.07439171522855759, -0.0901402160525322, 0.04300034046173096, 0.09216468036174774, 0.0018952717073261738, 0.03562697395682335, -0.03517807275056839, -0.050672952085733414, 0.05304177850484848, 0.0502886027097702, -0.032779473811388016, -0.09422416985034943, 0.04936708137392998, 0.032866522669792175, -0.04650266468524933, 0.04562251269817352, -0.1022084504365921, 0.05182008445262909, -0.019278857856988907, 0.07091102749109268, -0.14572885632514954, -0.09034879505634308, -0.011455779895186424, 0.02261858806014061, 0.05678395926952362, -0.06457190215587616, 0.021178746595978737, 0.0037268679589033127, 0.024922218173742294, -0.023279944434762, 0.005281184799969196, 0.024099480360746384, -0.024062316864728928, -0.14747211337089539, 0.019706059247255325, -0.023169133812189102, -0.09610411524772644, -0.16218236088752747, 0.09874071925878525, -0.009158656001091003], "changes": {"1wk": -1.8854156577992474, "1mo": -34.797733414882984}}, {"text": "PREMIUM Crinetics Pharmaceuticals Says US FDA Accepts NDA for Paltusotine to Treat Acromegaly MT Newswires Mon, Dec 9, 2024, 5:21 PM In This Article: CRNX -3.75% Crinetics Pharmaceuticals (CRNX) said Monday that the US Food and Drug Administration had accepted i PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a subscription? Sign in Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2024-12-09T17:21:25", "sentiment": {"score": 0.08824907522648573, "confidence": 0.09827053546905518, "probabilities": {"positive": 0.09827053546905518, "negative": 0.010021460242569447, "neutral": 0.8917080760002136}}, "embedding": [-0.13142064213752747, -0.12282086163759232, -0.08114491403102875, -0.062013182789087296, 0.01768745481967926, 0.10719707608222961, -0.0798090249300003, 0.14654108881950378, -0.028699252754449844, 0.09322413057088852, -0.029764661565423012, 0.1580144464969635, -0.05575016885995865, 0.060326602309942245, -0.06919465959072113, -0.004244415555149317, 0.17893986403942108, -0.11419772356748581, 0.17157429456710815, -0.04262547567486763, -0.07351730018854141, 0.08553537726402283, 0.050952374935150146, -0.02665173076093197, -0.0941174179315567, -0.06650839745998383, -0.21035756170749664, -0.02361304871737957, 0.08554428815841675, -0.052638277411460876, 0.10726043581962585, -0.020798983052372932, 0.1426386684179306, -0.10137972235679626, 0.034841857850551605, -0.1071835532784462, 0.001867692219093442, -0.07468769699335098, -0.05398847535252571, 0.1786009818315506, 0.17253483831882477, 0.021715756505727768, -0.11048971116542816, 0.20906583964824677, 0.08811283856630325, -0.19978906214237213, -0.17259123921394348, 0.18044617772102356, -0.022874165326356888, 0.2829000651836395, -0.018930593505501747, -0.26253142952919006, 0.07800524681806564, 0.011837990023195744, -0.06928950548171997, 0.07970565557479858, -0.3127736449241638, 0.050830721855163574, 0.13778798282146454, 0.0644812285900116, -0.019065039232373238, 0.0350644551217556, -0.025484653189778328, 0.07724275439977646, 0.05642377957701683, 0.006839768495410681, -0.0204173531383276, 0.01181564200669527, 0.18045148253440857, -0.03979979082942009, 0.11298758536577225, -0.06377789378166199, 0.1165008544921875, -0.15301825106143951, 0.0378534197807312, 0.14153769612312317, 0.1391177773475647, -0.1552213728427887, 0.021769607439637184, -0.1336888074874878, -0.1622719168663025, 0.06782960146665573, 0.22602127492427826, -0.12644867599010468, 0.10893075913190842, -0.037418968975543976, -0.06488905847072601, 0.05249280110001564, -0.08955655992031097, -0.0848357304930687, 0.2791267931461334, -0.13718190789222717, 0.07974141091108322, 0.056679338216781616, -0.129760280251503, -0.00579818245023489, -0.0965103879570961, -0.043679337948560715, -0.18924209475517273, 0.002565451432019472, -0.03842850401997566, 0.05515894293785095, -0.24730835855007172, -0.08571068942546844, -0.0528964102268219, -0.004931775853037834, 0.09778264164924622, 0.14733590185642242, -0.005593438632786274, 0.16804127395153046, -0.19146817922592163, 0.2580900490283966, 0.00564641784876585, -0.061229802668094635, -0.01905744895339012, 0.09230959415435791, -0.22842088341712952, -0.0291792843490839, 0.17681850492954254, -0.02839999459683895, -0.08129216730594635, -0.032107509672641754, -0.10574870556592941, -0.07574065774679184, 0.08999037742614746, 0.07601741701364517, -0.013010692782700062, 1.3350340604206207e-32, -0.045141637325286865, 0.12200301885604858, 0.14853450655937195, -0.12687994539737701, -0.04767250269651413, 0.10229163616895676, 0.004275870975106955, -0.0010114439064636827, -0.14490363001823425, -0.14215517044067383, -0.14341743290424347, 0.17480698227882385, 0.0006940782768651843, 0.15963083505630493, -0.2497957944869995, -0.25124916434288025, -0.0794307142496109, 0.09757012873888016, 0.1725429743528366, 0.023080788552761078, 0.03619098663330078, -0.029468173161149025, 0.018058618530631065, 0.06129177659749985, -0.14258675277233124, 0.06948910653591156, 0.13461382687091827, 0.21354636549949646, 0.26454609632492065, 0.048153504729270935, -0.051093410700559616, -0.023397136479616165, 0.08480750769376755, -0.00025250233011320233, 0.041303884238004684, 0.022467292845249176, 0.020191596820950508, -0.1251526176929474, -0.10463646799325943, 0.03396116942167282, 0.041694678366184235, 0.05305767431855202, -0.11600704491138458, -0.06211723014712334, 0.009670855477452278, -0.10818587243556976, -0.10787545144557953, -0.1145671010017395, -0.08795521408319473, -0.24022869765758514, -0.05312043055891991, 0.18253262341022491, -0.009328662417829037, -0.00955513771623373, -0.041971657425165176, -0.049464210867881775, -0.20201142132282257, -0.0364709198474884, 0.21807529032230377, -0.1711149960756302, 0.19582869112491608, -0.09492108225822449, 0.006939093582332134, -0.19018134474754333, -0.1586369127035141, 0.07117818295955658, -0.12057376652956009, -0.22996988892555237, -0.07115541398525238, -0.011862020008265972, 0.06375891715288162, 0.03361648693680763, -0.04176771268248558, 0.15240958333015442, 0.08931609988212585, -0.016744231805205345, -0.005079843103885651, 0.12105206400156021, -0.0015449344646185637, 0.040112659335136414, 0.043676115572452545, -0.03970847651362419, 0.12378948926925659, 0.12724468111991882, 0.1396160125732422, -0.12800239026546478, -0.0751633271574974, -0.04064326733350754, 0.19031420350074768, -0.03009549155831337, 0.07834485173225403, 0.014805263839662075, -0.13105718791484833, 0.13613811135292053, -0.019559204578399658, -1.2076872472662729e-32, -0.19158029556274414, -0.05147458240389824, 0.01565348543226719, 0.039418309926986694, -0.2199944406747818, -0.029274316504597664, -0.02980884350836277, 0.09862612187862396, 0.31145673990249634, -0.14172659814357758, 0.1967850774526596, 0.006586149800568819, -0.03587380796670914, -0.12334933876991272, 0.007199183572083712, 0.08350871503353119, -0.035265903919935226, -0.12379495054483414, -0.121243916451931, 0.003323726588860154, -0.1108166053891182, 0.04110139608383179, -0.09946514666080475, 0.12771566212177277, 0.17941606044769287, 0.11101555824279785, -0.0029477255884557962, 0.1318458616733551, 0.10454413294792175, 0.00041367890662513673, -0.002199152484536171, 0.01422753743827343, -0.2782956659793854, 0.19424624741077423, -0.11536436527967453, 0.08964662253856659, 0.07443905621767044, 0.07948726415634155, -0.0933787077665329, -0.029960623010993004, 0.190351665019989, -0.0525226965546608, -0.09516817331314087, 0.06679415702819824, 0.1339423954486847, 0.026071038097143173, -0.0021209039259701967, 0.08829814195632935, 0.013985206373035908, 0.07922761887311935, -0.1269041746854782, -0.04779206961393356, 0.13529591262340546, -0.02991146221756935, 0.14084190130233765, 0.02987264283001423, 0.06983350217342377, -0.026425492018461227, 0.14907197654247284, -0.04210546612739563, 0.14462874829769135, 0.0729258805513382, -0.20886515080928802, -0.0966242253780365, 0.16670428216457367, 0.08040548115968704, 0.13628940284252167, 0.12055134773254395, 0.23486486077308655, 0.015050881542265415, 0.00010445700900163502, 0.06889811903238297, -0.05515894293785095, -0.10828794538974762, -0.05017014592885971, 0.12966930866241455, -0.02894245646893978, -0.18817724287509918, -0.2113753706216812, -0.06583932787179947, 0.0631835013628006, -0.17545124888420105, 0.10254646837711334, 0.09120283275842667, 0.0494641549885273, 0.008185133337974548, 0.19852623343467712, -0.19862903654575348, -0.06485442817211151, 0.17695915699005127, -0.15626473724842072, -0.20463253557682037, -0.197592630982399, 0.12313830852508545, 0.1751268208026886, -9.978749204719861e-08, 0.1967964768409729, -0.0685918927192688, 0.07481592893600464, 0.0057021682150661945, 0.02357480488717556, 0.0672471821308136, -0.2001495063304901, -0.19726350903511047, -0.04458713158965111, 0.12219361215829849, -0.07391031831502914, -0.09467802941799164, 0.01447316538542509, -0.05452563241124153, -0.0692044273018837, 0.10248857736587524, 0.09379517287015915, 0.09352994710206985, 0.012490697205066681, -0.10381599515676498, -0.21276496350765228, 0.14521236717700958, 0.1557304561138153, 0.06720001995563507, -0.00401989696547389, -0.04671822488307953, 0.09363726526498795, 0.09747353941202164, 0.086300790309906, -0.0763912945985794, -0.15222585201263428, 0.0049277483485639095, 0.12842902541160583, -0.015842637047171593, -0.008071438409388065, 0.0698409378528595, 0.011608334258198738, 0.10041455179452896, 0.04341937601566315, -0.08182874321937561, -0.023263389244675636, -0.010644317604601383, 0.06722451001405716, -0.014587478712201118, -0.05294483155012131, -0.16806994378566742, -0.012003013864159584, -0.07043944299221039, 0.05576528608798981, -0.07944998890161514, 0.06353658437728882, -0.0157148577272892, 0.12392514944076538, -0.12479367107152939, -0.03504563122987747, 0.09828363358974457, -0.1854977309703827, -0.3241034150123596, -0.023249426856637, -0.17300619184970856, -0.05667945742607117, -0.2325313836336136, 0.1398453414440155, -0.05659925937652588], "changes": {"1wk": -5.227833169042633, "1mo": -12.71635623236452}}, {"text": "Crinetics Pharmaceuticals Inc (CRNX) Q3 2024 Earnings Call Highlights: Strategic Advances and ... GuruFocus News Wed, Nov 13, 2024, 10:18 AM 3 min read In This Article: CRNX -3.75% Release Date: November 12, 2024 For the complete transcript of the earnings call, please refer to the full earnings call transcript . Positive Points Crinetics Pharmaceuticals Inc ( NASDAQ:CRNX ) has submitted its first NDA for paltusotine, a next-generation therapy for acromegaly, and anticipates FDA filing notification in December. The company is preparing for the anticipated launch of paltusotine by building commercial capabilities and engaging with payers for formulary placement. Crinetics Pharmaceuticals Inc ( NASDAQ:CRNX ) has a strong financial position with approximately $1.4 billion in cash and investments, projected to fund operations into 2029. The company is advancing a robust pipeline with multiple candidates, including CRN 9,682, a novel nonpeptide drug conjugate for cancer treatment. Positive results from a phase two study for carcinoid syndrome were reported, with plans to start a phase three trial on schedule. Negative Points There were no revenues for the quarter ended September 30, 2024, compared to $0.3 million for the same period in 2023. Research and development expenses increased to $61.9 million for the quarter, up from $43.8 million in the same period in 2023, driven by higher personnel costs and manufacturing activities. General and administrative expenses rose to $25.9 million for the quarter, compared to $15.5 million in the same period in 2023, due to higher personnel costs and commercial planning activities. Net loss for the quarter was $76.8 million, compared to a net loss of $57.5 million for the same period in 2023. The company anticipates increased R&D and SG&A expenses as it prepares for the potential launch of paltusotine and initiates multiple phase three studies. Q & A Highlights Warning! GuruFocus has detected 5 Warning Signs with CRNX. Q : Can you provide more details about the NDC program, CRN 9,682, and its advantages over ADCs or radiotherapies? A : The NDC platform is an extension of ideas from radio nets, offering advantages over ADCs by targeting GPCRs, which are difficult for antibodies. NDCs allow for selective internalization and intracellular cleavage, offering simpler synthesis and potential advantages in pharmacokinetics. We aim to learn more about these advantages in real-world settings, particularly with neuroendocrine tumors. - Dr. Scott Struthers, CEO Q : With several products entering the clinic next year, when can we expect Phase 1 data, and how did you choose the MMAE toxin for CRN 9,682? A : We anticipate a flow of information over the next year but won't provide precise timelines. CRN 9,682 is not a direct homologue of paltusotine; it was optimized for selective binding and internalization. MMAE was chosen due to its established use in ADCs, but we are exploring alternative payloads. - Dr. Scott Struthers, CEO Story Continues Q : How are you approaching candidate selection for obesity indications in 2025, given the competitive landscape? A : We focus on selecting candidates that can be easily manufactured and have good tolerability. We aim for a best-in-class profile for small molecule GLP-1 agonists, ensuring they meet high standards before advancing. - Dr. Scott Struthers, CEO Q : What are the potential advantages of non-peptide compounds in the obesity space compared to other assets? A : Non-peptide compounds offer advantages in manufacturing and allow exploration of broader chemical space and delivery methods. This flexibility helps optimize pharmacokinetic activities and clinical profiles, addressing one of the biggest public health challenges. - Dr. Scott Struthers, CEO Q : Can you discuss the common toxicities associated with MMAE ADCs and your confidence in balancing efficacy and tolerability? A : We are aware of MMAE's common toxicities and have designed CRN 9,682 to minimize circulating free MMAE, ensuring good preclinical safety margins. The conjugates clear rapidly from systemic circulation, while cleaved MMAE accumulates in tumor cells. - Dr. Scott Struthers, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript . This article first appeared on GuruFocus . View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2024-11-13T10:18:49", "sentiment": {"score": 0.8310759589076042, "confidence": 0.9025793075561523, "probabilities": {"positive": 0.9025793075561523, "negative": 0.07150334864854813, "neutral": 0.025917330756783485}}, "embedding": [-0.06287361681461334, -0.12332480400800705, -0.09485631436109543, -0.13797320425510406, -0.016107231378555298, 0.00456410413607955, 0.015750447288155556, 0.22659584879875183, 0.14730533957481384, 0.10439103841781616, -0.12534546852111816, 0.03300567716360092, 0.11565367877483368, 0.06762756407260895, -0.171133354306221, -0.012176906690001488, 0.015541329979896545, -0.13799455761909485, 0.04595724865794182, 0.016294017434120178, -0.04344834387302399, 0.042724039405584335, 0.08380082249641418, 0.010890623554587364, -0.019369207322597504, -0.029543781653046608, -0.07464243471622467, 0.040180403739213943, -0.09265883266925812, -0.0051807742565870285, 0.10919210314750671, 0.13500827550888062, 0.05334708094596863, -0.0663997009396553, 0.028828974813222885, 0.05356423184275627, -0.06250539422035217, 0.08179523795843124, -0.07764863967895508, 0.04743872210383415, -0.039378393441438675, -0.009500088170170784, -0.09898948669433594, 0.06714609265327454, 0.0822981595993042, -0.23491713404655457, -0.09404157102108002, 0.049298275262117386, 0.01244748942553997, 0.14582094550132751, -0.04452407360076904, -0.180295929312706, 0.0024245958775281906, 0.12025761604309082, -0.06332055479288101, 0.07404108345508575, -0.27515339851379395, 0.03603804484009743, 0.02795504406094551, 0.08742152154445648, -0.0034367889165878296, 0.03474067896604538, 0.024129746481776237, -0.03492913395166397, 0.23840536177158356, 0.0647948607802391, -0.0298034455627203, -0.07498541474342346, 0.05056293308734894, 0.07071040570735931, 0.098350889980793, -0.103759765625, -0.01347521971911192, -0.13741672039031982, -0.031692951917648315, 0.13874618709087372, 0.1470108926296234, 0.046057067811489105, -0.0013195062056183815, -0.13964450359344482, 0.051679082214832306, 0.07270654290914536, 0.04870142415165901, -0.037786222994327545, -0.023325467482209206, 0.06335606426000595, 0.08049418032169342, 0.11191565543413162, 0.06864646822214127, 0.005808900110423565, 0.15093445777893066, 0.028140492737293243, 0.04393405839800835, -0.0635928064584732, -0.020041098818182945, -0.006483464501798153, -0.0456726998090744, 0.00030849967151880264, 0.03302682191133499, 0.0067330216988921165, 0.07595749944448471, 0.03209242597222328, -0.16893339157104492, -0.18377864360809326, -0.09688003361225128, -0.035528454929590225, 0.12152113020420074, 0.045503031462430954, -0.043486952781677246, 0.028432656079530716, -0.17260900139808655, 0.1693345308303833, -0.03895529732108116, -0.09301957488059998, -0.018227318301796913, 0.22886934876441956, -0.1571284681558609, 0.024095183238387108, 0.20171141624450684, 0.03773774951696396, -0.010928069241344929, -0.05270452797412872, -0.0993063822388649, -0.09851571917533875, 0.05981215834617615, 0.03200206905603409, -0.14064666628837585, 1.154800948270412e-32, -0.07526067644357681, 0.14217902719974518, 0.09779565036296844, -0.025427203625440598, -0.02939475327730179, 0.08653047680854797, 0.007479723542928696, 0.031160958111286163, -0.15990258753299713, -0.1286836862564087, -0.17622748017311096, 0.10393814742565155, -0.035581305623054504, -0.007570821791887283, -0.029108289629220963, -0.17718811333179474, -0.10023811459541321, 0.0792926773428917, -0.06128263473510742, -0.08565370738506317, -0.0664554089307785, -0.004875051788985729, -0.06323312222957611, 0.10460519045591354, -0.005033282563090324, 0.06186532974243164, -0.024154413491487503, 0.16921260952949524, 0.09052345901727676, -0.011568505316972733, -0.06332532316446304, 0.036318548023700714, 0.07560862600803375, -0.053603388369083405, -0.05768246576189995, -0.020712073892354965, -0.10125567018985748, -0.13855856657028198, 0.026492245495319366, 0.09904098510742188, -0.05828755348920822, 0.1077752336859703, 0.003028926206752658, -0.160755455493927, 0.08037927001714706, -0.09297984838485718, -0.06468165665864944, 0.009264010936021805, -0.11345501244068146, -0.06774941831827164, -0.04896135628223419, 0.097928985953331, 0.020902156829833984, -0.03117561899125576, -0.03827745467424393, -0.03255762532353401, -0.06753954291343689, -0.13071468472480774, 0.053475428372621536, 0.14758260548114777, 0.004381248727440834, -0.004272285848855972, -0.0760294571518898, -0.0015842271968722343, -0.1414290815591812, 0.1300169974565506, -0.04990508034825325, -0.11041335016489029, 0.07178060710430145, 0.1436985433101654, -0.045655228197574615, -0.00501229427754879, 0.12174127250909805, 0.03387093171477318, 0.22594283521175385, -0.04934784024953842, -0.01001406367868185, 0.10985751450061798, -0.0457351915538311, 0.0855318158864975, -0.006075773388147354, -0.007842125371098518, -0.013890178874135017, 0.09440310299396515, 0.08103235810995102, -0.132563978433609, -0.03753051161766052, -0.025432903319597244, -0.03364965319633484, -0.004323058761656284, 0.06237698346376419, -0.07266087085008621, -0.10228009521961212, 0.12903368473052979, -0.019847992807626724, -8.921024258378072e-33, -0.10782063752412796, 0.021156545728445053, 0.047736719250679016, -0.02051636204123497, -0.03673630580306053, 0.07081873714923859, 0.09229524433612823, -0.12452472746372223, 0.10060228407382965, -0.12079767882823944, 0.09417884796857834, 0.04350120201706886, -0.057104069739580154, -0.08886176347732544, -0.08500023186206818, 0.025703024119138718, 0.024375542998313904, -0.14785248041152954, 0.011200686916708946, -0.044804830104112625, 0.11019577085971832, 0.21036215126514435, -0.08734199404716492, 0.09983538091182709, -7.724645547568798e-05, 0.09978587925434113, 0.04838256537914276, 0.10592042654752731, 0.10617084801197052, 0.036002904176712036, -0.05998586490750313, -0.028903646394610405, -0.2436586618423462, 0.14677312970161438, -0.002004246925935149, 0.015137817710638046, 0.09131133556365967, -0.10586519539356232, -0.04603079333901405, -0.08344454318284988, 0.14015242457389832, 0.05863328278064728, -0.0534043163061142, -0.017650438472628593, 0.025119606405496597, 0.011393584311008453, 0.022884704172611237, 0.028860963881015778, 0.1104583740234375, 0.07503630220890045, -0.048086557537317276, -0.03145100921392441, -0.004643818363547325, -0.004903996363282204, 0.03529772907495499, 0.06913253664970398, 0.0424320250749588, 0.02376004122197628, 0.0426454022526741, 0.08911776542663574, 0.10444238781929016, 0.07195352762937546, -0.05666156858205795, -0.03272869437932968, 0.029470091685652733, 0.0878152996301651, 0.07839690148830414, 0.14107829332351685, 0.11323078721761703, -0.16864590346813202, -0.07307282090187073, -0.024688981473445892, 0.06759405881166458, -0.09250770509243011, -0.10791485756635666, 0.07569301873445511, -0.021188296377658844, -0.15324419736862183, -0.119886115193367, -0.020023930817842484, -0.002955229952931404, -0.10750775784254074, 0.06801023334264755, 0.0895322784781456, 0.008298851549625397, 0.19307968020439148, 0.04368710517883301, -0.09764201939105988, -0.0610857829451561, 0.07446016371250153, -0.06668418645858765, -0.06803429871797562, -0.014971630647778511, 0.12786608934402466, 0.11740906536579132, -9.987257953980588e-08, 0.14202801883220673, -0.037568069994449615, 0.11085423082113266, -0.11271672695875168, 0.048813387751579285, -0.09506487101316452, -0.04270247370004654, -0.01705794408917427, -0.020234353840351105, 0.15947477519512177, -0.03653734177350998, 0.009282523766160011, -0.16329661011695862, 0.05696579068899155, -0.13607367873191833, 0.1573243886232376, -0.03635488077998161, 0.0330219641327858, -0.04996296763420105, -0.0775587186217308, -0.1040012389421463, 0.06822650134563446, -0.02439737692475319, 0.031658902764320374, 0.038965724408626556, -0.08796824514865875, 0.04831089824438095, 0.15087474882602692, 0.004551457241177559, 0.022753817960619926, 0.0051697781309485435, -0.06802347302436829, 0.1244177371263504, 0.025839913636446, -0.07329708337783813, -0.05563823878765106, 0.041120193898677826, 0.08062661439180374, 0.009976696223020554, 0.136929452419281, 0.0024279498029500246, 0.007581297308206558, -0.016623839735984802, -0.0028416160494089127, -0.04680989310145378, -0.12302027642726898, -0.21077394485473633, -0.04266630858182907, 0.015316713601350784, -0.13004794716835022, 0.12454245239496231, 0.0056228190660476685, 0.022273316979408264, -0.12595777213573456, 0.003456940408796072, 0.03672094643115997, -0.08517707139253616, -0.1298505663871765, -0.03352908790111542, -0.06929813325405121, -0.01537082064896822, -0.1944516897201538, 0.13197186589241028, 0.04737260937690735], "changes": {"1wk": -6.364562315917544, "1mo": -5.6008135431339205}}, {"text": "Crinetics Announces FDA Acceptance of New Drug Application for Paltusotine for Adult Patients with Acromegaly Crinetics Pharmaceuticals, Inc. Mon, Dec 9, 2024, 4:00 PM 4 min read In This Article: CRNX -3.75% Crinetics Pharmaceuticals, Inc. FDA Assigns a Prescription Drug User Fee Act Target Action Date of September 25, 2025 SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for investigational candidate paltusotine for the treatment and long-term maintenance therapy of acromegaly in adults. If approved, paltusotine will be the first and only once-daily, oral, selective somatostatin receptor type 2 nonpeptide agonist available for adults living with acromegaly. \u201cWith our patient-centered clinical development of paltusotine, we were guided by an unwavering ambition to deliver a new generation of treatment that provides a once-daily, oral alternative to the currently marketed peptide analog drugs,\u201d said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. \u201cWe look forward to working with the FDA throughout the review of our new drug application, as we also prepare for a potential commercial launch by building out our infrastructure and engaging with payers and the endocrinology community.\u201d The NDA submission for once-daily, oral paltusotine included data from the PATHFNDR-1 ( NCT04837040 ) and PATHFNDR-2 ( NCT05192382 ) Phase 3 clinical trials, which evaluated paltusotine\u2019s safety and efficacy in previously treated and medically untreated adults, respectively. The FDA has set a Prescription Drug User Fee target action date of September 25, 2025, for completing review of the NDA. The FDA also confirmed that an advisory committee meeting is not anticipated as part of the application\u2019s review. Paltusotine was granted Orphan Drug Designation for the treatment of acromegaly by the FDA in July 2020. This designation is provided to drugs defined as being intended for the safe and effective treatment, diagnosis or prevention of rare diseases that affect fewer than 200,000 people in the United States. ABOUT PALTUSOTINE Crinetics\u2019 lead development candidate, paltusotine, is the first investigational once-daily, oral, selectively-targeted somatostatin receptor type 2 (SST2) nonpeptide agonist that has completed Phase 3 clinical development for acromegaly and is initiating Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors. It was designed to be a once daily oral option for the control of acromegaly and the symptoms related to carcinoid syndrome. In Phase 3 studies, once-daily, oral paltusotine maintained IGF-1 levels and symptom control in patients with acromegaly who were switched from monthly injectable medications (PATHFNDR-1) and rapidly decreased IGF-1 levels and symptom burden in medically untreated acromegaly patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from a Phase 2 study in carcinoid syndrome demonstrated rapid and sustained reductions in flushing episodes and bowel movement frequency, which are the most common symptoms of carcinoid syndrome. Crinetics is preparing to initiate a Phase 3 trial for control of symptoms associated with carcinoid syndrome in patients with neuroendocrine tumors. Story Continues ABOUT ACROMEGALY Acromegaly is a serious rare disease generally caused by a benign pituitary adenoma (tumor) that secretes excess growth hormone (GH). Excess GH secretion causes excess secretion of insulin-like growth factor-1 (IGF-1) from the liver. Prolonged exposure to increased levels of IGF-1 and GH leads to progressive and serious systemic complications, often resulting in bone, joint, cardiovascular, metabolic, cerebrovascular, or respiratory disease. Acromegaly symptoms include headache, joint aches, fatigue, sleep apnea, severe sweating, hyperhidrosis/oily skin, bone and cartilage overgrowth, abnormal growth of hands and feet, enlargement of heart, liver and other organs and alteration of facial features. Uncontrolled acromegaly results in increased mortality and has a debilitating impact on daily functioning and quality of life. Monthly depot injections of peptide somatostatin receptor ligands are the most common pharmacologic treatment for people suffering with acromegaly. However, these depots typically require many months to achieve the correct dose level. People suffering with acromegaly often experience a return of symptoms towards the end of the monthly injection cycle and many must adjust their injection frequency to more often than monthly 1 . Further, these depots are difficult to administer and employ large gauge needles that are commonly associated with pain, injection site reactions and an increased burden on the lives of patients. ABOUT\u00a0CRINETICS PHARMACEUTICALS Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Crinetics\u2019 lead development candidate, paltusotine , is the first investigational once-daily, oral, selective somatostatin receptor type 2 (SST2) nonpeptide agonist that is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant an investigational, first-in-class, oral ACTH antagonist that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing\u2019s disease. All of the company\u2019s drug candidates are orally delivered, small molecule, new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves\u2019 disease (including thyroid eye disease), diabetes, obesity and GPCR-targeted oncology indications. FORWARD-LOOKING STATEMENTS This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the NDA review process and the expected timing of the completion of the FDA\u2019s review of the NDA for paltusotine for the treatment or maintenance of treatment of acromegaly in the United States, the therapeutic potential and clinical benefits or safety profile of paltusotine for patients with acromegaly and carcinoid syndrome, the plans and timelines for the commercial launch paltusotine for acromegaly, if approved, the expected timing of initiation of a Phase 3 program of paltusotine for carcinoid syndrome or the pathway for regulatory approval, the clinical development of atumelnant, including the therapeutic potential and clinical benefits or safety profile thereof, and the potential of our other research, discovery, and clinical trial programs. In some cases, you can identify forward-looking statements by terms such as \u201cmay,\u201d \u201cwill,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201ccould,\u201d \u201cintend,\u201d \u201ctarget,\u201d \u201cproject,\u201d \u201ccontemplates,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpredicts,\u201d \u201cpotential,\u201d \u201cupcoming\u201d or \u201ccontinue\u201d or the negative of these terms or other similar expressions. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, including, without limitation, the expected timing of additional data and topline results from studies of atumelnant in CAH and Cushing\u2019s syndrome; the possibility of unfavorable new clinical data and further analyses of existing clinical data; potential delays in the commencement, enrollment and completion of clinical trials and the reporting of data therefrom; we may not be able to obtain, maintain and enforce our patents and other intellectual property rights, and it may be prohibitively difficult or costly to protect such rights; geopolitical events may disrupt Crinetics\u2019 business and that of the third parties on which it depends, including delaying or otherwise disrupting its clinical studies and preclinical studies, manufacturing and supply chain, or impairing employee productivity; unexpected adverse side effects or inadequate efficacy of the Company\u2019s product candidates that may limit their development, regulatory approval and/or commercialization; the Company\u2019s dependence on third parties in connection with product manufacturing, research and preclinical and clinical testing; the success of Crinetics\u2019 clinical studies and nonclinical studies; regulatory developments in the United States and foreign countries; the timing and outcome of research, development and regulatory review is uncertain, and Crinetics\u2019 drug candidates may not advance in development or be approved for marketing; and the other risks and uncertainties described in the Company\u2019s periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company\u2019s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading \u201cRisk Factors\u201d in Crinetics\u2019 periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023 and its Quarterly reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024 and September 30, 2024. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Investors: Gayathri Diwakar Head of Investor Relations gdiwakar@crinetics.com (858) 345-6340 Media: Natalie Badillo Head of Corporate Communications nbadillo@crinetics.com (858) 345-6075 1 Data on file. View Comments Terms and Privacy Policy Privacy Dashboard Recommended Stories", "symbol": "CRNX", "date": "2024-12-09T16:00:00", "sentiment": {"score": 0.2861029291525483, "confidence": 0.295558899641037, "probabilities": {"positive": 0.295558899641037, "negative": 0.009455970488488674, "neutral": 0.6949850916862488}}, "embedding": [-0.0201889555901289, -0.15448862314224243, -0.09575245529413223, -0.05265512317419052, -0.02226216346025467, 0.06634700298309326, -0.07358649373054504, 0.2665330171585083, 0.12807919085025787, 0.07955195009708405, -0.06845763325691223, 0.05301253870129585, -0.044671736657619476, 0.11736714839935303, -0.046830158680677414, 0.044312890619039536, 0.1453016698360443, -0.05295833572745323, 0.07823008298873901, 0.04102335870265961, 0.03428107500076294, 0.1147390604019165, 0.09030227363109589, 0.06677550822496414, -0.1746465265750885, -0.018713703379034996, -0.1653735339641571, -0.07206077873706818, -0.1325170397758484, -0.028475096449255943, 0.13988932967185974, 0.12594075500965118, 0.08847331255674362, -0.06160249933600426, -0.02385898120701313, -0.02755611017346382, -0.10169012099504471, -0.02454894781112671, -0.04203959181904793, 0.06312935799360275, -0.014005923643708229, -0.03329985588788986, -0.11252501606941223, 0.12364286184310913, 0.08928140252828598, -0.23024693131446838, -0.13899856805801392, 0.14833694696426392, -0.03355058282613754, 0.27877113223075867, 0.03953235223889351, -0.13547460734844208, 0.0915539413690567, 0.03335500508546829, -0.08319827914237976, 0.05163002759218216, -0.19402743875980377, 0.017590682953596115, 0.06352381408214569, 0.07318076491355896, -0.10855481028556824, -0.005389869213104248, 0.006076812744140625, -0.021303288638591766, 0.06378547847270966, 0.03048579953610897, -0.027573324739933014, -0.0981370285153389, 0.129003643989563, 0.05389433354139328, 0.04521273821592331, -0.09224368631839752, 0.11360092461109161, -0.0009104683995246887, -0.008238524198532104, 0.07600225508213043, 0.1749015748500824, 0.06659962236881256, 0.028696240857243538, -0.2012975960969925, -0.043229036033153534, 0.04631923511624336, 0.056485481560230255, -0.0009601353667676449, -0.005284027196466923, 0.01546651404350996, -0.089638352394104, 0.12253917753696442, 0.030101127922534943, 0.03506598621606827, 0.20118212699890137, 0.04716124013066292, 0.007368268445134163, 0.0122914407402277, 0.019877448678016663, -0.06467416882514954, -0.07860252261161804, 0.03356282413005829, -0.055029451847076416, -0.008599955588579178, -0.024411248043179512, -0.015230385586619377, -0.20625635981559753, -0.03278781473636627, 0.012745549902319908, -0.04085849970579147, 0.06485042721033096, -0.12554341554641724, 0.005499944090843201, 0.061003103852272034, -0.17099371552467346, 0.08001186698675156, 0.007134962826967239, 0.035614192485809326, 0.019701912999153137, 0.15507759153842926, -0.10034994781017303, 0.02295845001935959, 0.21865874528884888, 0.06482100486755371, 0.02131371945142746, -0.02360798604786396, -0.005681672133505344, -0.0795462355017662, 0.05370355397462845, 0.08852449804544449, 0.003690971527248621, 1.1454979390412105e-32, -0.08855609595775604, 0.026062797755002975, 0.06770747154951096, -0.029790757223963737, -0.10171590745449066, 0.029896406456828117, 0.02518048882484436, 0.08979366719722748, -0.11200153827667236, -0.11882534623146057, -0.11437413096427917, -0.02178671583533287, 0.0396682471036911, 0.14454972743988037, -0.12497670203447342, -0.16127336025238037, -0.05131538212299347, 0.05528918281197548, 0.044265568256378174, -0.02126079797744751, 0.02899393066763878, 0.049513496458530426, -0.022870928049087524, 0.12199284136295319, -0.12574388086795807, 0.05982866510748863, 0.04322844371199608, 0.13842567801475525, 0.09156276285648346, -0.001925069373100996, -0.02116542123258114, 0.025876644998788834, 0.14749068021774292, -0.06801426410675049, -0.0385095477104187, -0.09163807332515717, 0.01779724843800068, -0.08205186575651169, -0.04642868414521217, 0.05923708528280258, 0.00044390279799699783, 0.07278776913881302, -0.026514187455177307, -0.07432705163955688, 0.0900438129901886, -0.19284987449645996, -0.09917566180229187, -0.05723593384027481, -0.13196799159049988, -0.12880676984786987, -0.0021202396601438522, 0.0755879133939743, 0.05728999525308609, 0.03369387984275818, -0.0984259694814682, -0.016597460955381393, -0.23561838269233704, -0.07588893920183182, 0.09816581010818481, -0.031134657561779022, 0.049741096794605255, 0.022299865260720253, -0.05657479912042618, -0.051936253905296326, -0.17830263078212738, 0.07132289558649063, -0.026682306081056595, -0.15459087491035461, -0.0704440250992775, 0.0703662633895874, 0.06063181906938553, 0.036815084517002106, 0.07832834124565125, 0.07290476560592651, 0.15428946912288666, -0.07143843173980713, 0.1114458441734314, 0.1648438721895218, -0.05949650704860687, -0.017545968294143677, -0.01003950648009777, 0.041543424129486084, -0.07584352791309357, 0.159847229719162, 0.11639559268951416, -0.1250438094139099, -0.036639079451560974, -0.10282672196626663, -0.04032094404101372, -0.05402974784374237, 0.09747256338596344, -0.09498046338558197, -0.09303636848926544, 0.12726888060569763, 0.10374854505062103, -9.95977555542111e-33, -0.10760974884033203, 0.04852255806326866, 0.020875778049230576, -0.017908373847603798, -0.016068395227193832, 0.04680933803319931, -0.0030624414794147015, -0.043723270297050476, 0.18015258014202118, -0.28638938069343567, 0.00014089606702327728, 0.03190245479345322, 0.008160358294844627, -0.1124684140086174, -0.04418082535266876, 0.12234347313642502, -0.0918121337890625, -0.10738987475633621, -0.17183470726013184, 0.0794859379529953, 0.04519493132829666, 0.09052734076976776, -0.15756556391716003, 0.001686474890448153, 0.1292232871055603, 0.07348252832889557, 0.07735823094844818, 0.06553400307893753, 0.09595067799091339, -0.01288918498903513, -0.0424966886639595, -0.013262220658361912, -0.21059447526931763, 0.049654535949230194, -0.025461792945861816, 0.0006472021341323853, -0.0017420798540115356, -0.053515706211328506, -0.13010764122009277, -0.06686919927597046, 0.026487385854125023, 0.07822633534669876, -0.07304958254098892, -0.0026202723383903503, 0.0938701257109642, 0.080055832862854, 0.0611039362847805, 0.023234721273183823, 0.013663548976182938, 0.05924228951334953, -0.11620475351810455, -0.09862031042575836, 0.048489414155483246, -0.0315341092646122, 0.107325978577137, -0.028047913685441017, 0.04843134433031082, -0.07154624164104462, 0.023708146065473557, -0.003054582979530096, 0.10808885097503662, 0.06914912909269333, -0.035429053008556366, 0.012371367774903774, 0.1888647824525833, 0.02757127955555916, 0.08512227237224579, 0.11850664019584656, 0.1549980193376541, -0.06110810488462448, -0.07793131470680237, -0.004934681113809347, -0.075002521276474, -0.03235932067036629, -0.03877847269177437, 0.08682370185852051, 0.00679747574031353, -0.21286627650260925, -0.16788935661315918, -0.03885389864444733, -0.04375099390745163, -0.08303897082805634, 0.056398969143629074, 0.07514908164739609, 0.040804192423820496, 0.041208665817976, 0.05521131306886673, -0.06448580324649811, -0.03281475603580475, 0.22932517528533936, -0.13490323722362518, -0.09070347249507904, -0.10458502173423767, 0.14355140924453735, 0.07738430052995682, -1.0011853390778924e-07, 0.1780645251274109, -0.025382205843925476, 0.025858324021100998, 0.02080293744802475, 0.023164529353380203, -0.008307903073728085, -0.05719040706753731, -0.1393415927886963, -0.10302026569843292, 0.07623576372861862, -0.0017238892614841461, 0.0758294016122818, -0.013264607638120651, -0.04107632860541344, -0.07719191163778305, 0.05887205898761749, 0.033553346991539, 0.04388435184955597, -0.054323114454746246, -0.023393942043185234, -0.15924963355064392, 0.0461353100836277, 0.05293697118759155, -0.03212691843509674, 0.05556737631559372, -0.08574224263429642, 0.04242341220378876, 0.12252674996852875, 0.05713072046637535, -0.0033527687191963196, -0.04520420730113983, -0.011203217320144176, 0.15516358613967896, -0.0031405517365783453, 0.0136891333386302, -0.06281200051307678, -0.03175308555364609, 0.12744277715682983, 0.04088682308793068, 0.07612871378660202, -0.0047917794436216354, 0.051322709769010544, -0.01020003855228424, 0.020409706979990005, 0.051990292966365814, -0.17254000902175903, -0.05352385714650154, -0.03942279890179634, 0.03989223390817642, -0.0808689221739769, -0.056747227907180786, 0.05606083199381828, 0.025525730103254318, -0.05185091122984886, 0.02453531324863434, 0.17200540006160736, -0.15170589089393616, -0.18717674911022186, 0.05425135791301727, -0.17190659046173096, -0.0420796200633049, -0.11693645268678665, 0.08473920077085495, 0.001753479242324829], "changes": {"1wk": -5.227833169042633, "1mo": -12.71635623236452}}]